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Vaccination is frequently acknowledged as the invention most beneficial to human development.  
In the past 50 years vaccination has advanced greatly in terms of consistency and efficacy, but, in order to 
improve accessibility of vaccines to underserved populations in the developing world, more research must 
be conducted to improve the safety of delivery, affordability and stability of vaccines.  This doctoral 
dissertation work has centered on the production of stable, dry powder vaccines and pharmaceuticals for 
inhalation.  A principal goal has been to prepare consistent dry powders of measles vaccine for delivery 
by inhalation with activity comparable to commercially available products. Samples of vaccines received 
from collaborators at the Serum Institute of India have been analyzed and characterized to ensure 
consistency.  This research has also uncovered a metastable crystal polymorph of myo-inositol (the 
primary excipient) as verified by powder X–ray diffraction and calorimetric studies.   Research has also 
been conducted on the development and optimization of a dry powder, protein subunit Human 
Papillomavirus vaccine for delivery by inhalation, sublingual pellet or reconstitution for injection. One 
can hope that this research will lead to the advancement of vaccination and pulmonary delivered 
pharmaceutical powders, aiding in the reduction of global mortality and morbidity due to vaccine 
preventable disease. 
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Chapter I Introduction 
________________ 
1.1 Vaccination 
The earliest recorded variant of vaccination was practiced in China in the 17
th
 
century.  The practice known as variolation was performed by placing a piece of cotton 
containing pus from a smallpox pustule into the nostril of a healthy child (Leug 1996).  
Presentation of the smallpox virus, compromised by the source patient’s immune response, 
resulted in an immune response in the recipient with reduced severity resulting in immune 
protection from smallpox infection in the future.  Another method of delivery was to blow 
powdered smallpox squama into the nostril of a healthy child using a small silver tube.  
Interestingly, this method “was said to be convenient for bringing the technique to remote 
areas” (Leung 1996), much like the motivation behind our development of an inhaled measles 
vaccine.   
Fortunately vaccination has been significantly developed since the inhalation of scabs 
and pus.  Vaccination is consistently cited as one of the inventions most beneficial to human 
development.  By providing preemptive protection, vaccines have greatly improved our 
quality of life, reducing the morbidity and mortality historically related to “unavoidable” 
diseases.  Vaccination results in the development of a natural immune response in the 
recipient, specific to the disease of interest.  While there are many different types of vaccines 
based on the identity of the antigen presented (DNA, Killed, Toxoid conjugated, etc.), the 
vaccine types that will be concentrated on in this dissertation will be:  subunit and live-
attenuated.   
The active ingredients in subunit vaccines are made up of deactivated or artificially 
produced immunogenic material related to the disease of interest.  In order to elicit an 
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immunogenic response to the disease, these materials usually mimic the antigens targeted by 
the immune system in an infection by the wild type disease agent, such as viral surface 
proteins.  Successful subunit vaccines generally require the addition of an adjuvant, or 
material intended to induce an increased immune response by, among other pathways, 
recruiting immune cells to the site of injection and promoting presentation of the antigen to 
the immune system.  Subunit vaccines can have a greater range of stability, due to the 
simplicity of the immunogenic components, but the adjuvant material included in the 
formulation may limit the stability of the entire formulation.  For instance, it is commonly 
observed that when a liquid formulation containing an alum-adjuvated antigen is frozen, the 
alum adjuvant frequently dissociates from the material, reducing the activity of the vaccine 
(Maa, Zhao et al. 2003).  It is for this reason that Hepatitis B and Gardasil, among many other 
liquid vaccines, cannot be lyophilized and are required to be stored between 2 and 8 °C.  
These liquid vaccines cannot be frozen, as they would loss activity, and require advanced 
temperature regulation during storage to remain viable. 
Live-attenuated vaccines use similar or altered versions of the disease agent that are 
still able to infect living cells and replicate, but have a diminished ability when compared to 
the wild type disease agent.  The living-attenuated agent is delivered and allowed to replicate, 
increasing the amount of immunogenic material in the recipient.  The immune system is able 
to neutralize the agent without the development of a full infection, in the process developing 
the ability to immunogenically respond to subsequent infections with the attenuated and wild 
type disease agent.  The first successful vaccine was a live virus vaccine for smallpox 
developed by Edward Jenner in 1798 (Artenstein 2010).  Before Jenner, the practice of 
variolation, or inoculation with pus from another patient suffering from smallpox, had been 
widely, but not commonly, used in England and abroad to provide protection from smallpox. 
Based on observations that milkmaids were less susceptible to smallpox, Jenner hypothesized 
that exposure to cowpox resulted in protection from the smallpox virus.  By placing bovine 
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tissue infected with cowpox over an open cut on a human patient, the patient was essentially 
infected with cowpox virus.  This virus was specifically adapted to infect bovine cells, and 
defend itself from the bovine immune system, so the human immune system was able to 
quickly neutralize this antigen and in doing so add a pathway of response to the “memory” of 
the immune system specific to this antigen.  The similarities between the cowpox and 
smallpox viruses allowed the human immune system to respond with immunogenic 
neutralization and protection from the extensive viral replication of wild type smallpox 
(Alzhanova and Fruh 2010).  The invention of the smallpox vaccine by Jenner and the 
vaccine campaigns that followed greatly increased the quality of life and reduced the 
mortality due to endemic smallpox.  With further development and advancement of the 
smallpox vaccine and well organized vaccination campaigns, natural smallpox infection was 
declared to be eradicated in 1980.  Even with the reported eradication of smallpox , there is 
still active research on smallpox vaccine development to respond to potential biological 
weaponization or some other pathway of smallpox reemergence (Henderson 2011) .  
Vaccines have been shown to greatly improve the quality of life of recipients but in practice, 
vaccination also has the potential to cause some health problems and death, in addition to 
controversy over vaccine delivery. 
As with any medical procedure involving the transfer of infected material to the 
bloodstream, vaccination always carries some inherent dangers.  In performing the Jenner 
vaccination procedure, particularly with the medical and sanitation practices of the 18
th
 and 
19
th
 century, occasional infection of the inoculating material with smallpox and other 
infective agents was observed (Hopkins 2002). Vaccinations with live-attenuated agents are 
infections and are associated with symptoms, such as rash, nausea and other negative health 
conditions that are similar to, but of less severity than, infection with the wild type disease 
(Siegrist 2007; Artenstein 2010).  In recipients with compromised immune systems, 
vaccination may not be as effective and may even cause health risks (Isaguliants 2007).  
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Other difficulties arise in the stability and potential for contamination of the vaccine material 
(Sood, Kumar et al. 1995).  In order to prevent cross contamination or the replication of other 
infective agents it is recommended that multidose vials of liquid vaccines be discarded after 6 
hours and  multidose vaccines are required to be formulated with preservatives (Clements, 
Larsen et al. 2004) .   
In 1998, a British gastroenterologist, Andrew Wakefield, and 12 other authors  
published a paper in the Lancet suggesting a connection between the delivery of the Measles, 
Mumps and Rubella (MMR) vaccine in infants and the subsequent diagnosis of  autistic 
symptoms.  Most anti-vaccination advocates attribute the observed autistic symptoms to the 
presence of thimerosal, an organomercury containing preservative commonly added to 
multidose vials of vaccine, in the MMR vaccinations.  This is an interesting assertion, as the 
MMR vaccine does not and has never contained thimerosal as a preservative (FDA 2010 ). 
When evidence of conflict of interest arose and the paper’s findings were not supported by 
subsequent research, 10 of the 12 authors retracted the interpretation of the results, while 
Wakefield continued to maintain the purported connection between MMR vaccination and 
Autism.  Despite the retraction of the paper by the Lancet and the denial of his right to 
practice medicine in the UK, Wakefield has continued to support his findings as verifiable 
and ethically obtained (Mnookin 2011). 
In recent times, many vocal groups have arisen promoting the belief that childhood 
vaccination (particularly with thimerosal containing vaccines) is a cause of autism.  Many 
prominent spokespeople in the anti-vaccination campaigns have arisen including celebrities 
Jim Carey and Jenny McCarthy, who, while not backed by extensive scientific research, 
assert that childhood and infant vaccination lead directly to autism.  Average rates of 
immunization in Britain dropped from 92 % to 73 % in 2002 and remain below 85% in 2011 
(Mnookin 2011)In the wake of anti-vaccination advocacy, intentionally unvaccinated 
individuals may undermine the “herd immunity” of a generally immune population.   
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The extensive vaccination of a population also introduces the added benefit of “herd 
immunity”.  When a sufficient proportion of a population, thought to be 70% to 95%, shows 
immunity to a disease, individuals in that population susceptible to the disease are sheltered 
from infection by avoiding exposure to the infectious agent (Brown, Shanley et al. 2011).  If a 
sufficient portion of the population rejects vaccination, reservoirs of the disease may appear 
in the general population which may lead to the infection of unimmunized infants and 
immunocompromised individuals.  Full compliance with mass vaccination campaigns is 
required for the complete eradication of a disease.In a 2008 measles outbreak in San Diego, 
75% of the cases were reported in intentionally unvaccinated individuals (Fine 1993). 
The standard method of vaccine delivery is intramuscular (i.m.) injection with 
disposable syringes.  This method consistently delivers the vaccine and does not require 
active participation on the part of the recipient, which makes it possible to deliver vaccines to 
infants.  There are, however, inherent dangers associated with vaccination by injection.  
Contact with the blood of vaccine recipients introduces the possibility of transmission of 
blood-borne diseases to the patients, healthcare providers and anyone exposed to the needles 
after use.  A 1999 study found that, in regions of the developing world, more than 50% of 
injections were unsafe and increase the risk of spreading HIV, hepatitis and other blood-
borne pathogens, with an estimated 20% of the new cases of hepatitis B attributable to unsafe 
injections (Sugerman, Barskey et al. 2010).  The use of needles also puts excessive risk on the 
healthcare providers, particularly in a mass vaccination campaign in areas with insufficient 
healthcare services.  A 2008 study found that 12.5% of percutaneous injuries occur when 
recapping needles and 31.2% occur when healthcare workers do not have proper facilities for 
sharps disposal (Simonsen, Kane et al. 1999).  This added danger can greatly discourage 
recruitment of skilled vaccine providers and  result in the removal from service of healthcare 
workers infected with a blood borne disease.  In order to avoid the inherent dangers of 
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injection, and the risk and cost of safe disposal of sharps, our research concentrates on the 
development of dry powder vaccines for inhalation. 
A recent review of possible innovations in measles vaccine delivery (Deuffic-Burban, 
Delarocque-Astagneau et al. 2011) has determined that delivery of measles vaccine as an 
inhalable dry powder may be the most promising new method of delivery, in terms of cost-
savings.  The study analyzed 4 different potential methods of vaccination: aerosolized liquid 
vaccine,  jet injector, inhalable dry powder and DNA-based vaccine.  These methods were 
analyzed based on the cost of dose per child and  potential to reduce mortality and morbidity 
for the estimated >4.2 billion potential candidates for a new vaccine.  The results of this study 
clearly distinguish inhaled dry powder measles vaccine as the method with the greatest 
potential for cost savings.  Inhaled dry powder vaccine was estimated to result in a cost 
impact of -$689.4 million dollars over 40 years (compared to the -$154.1 million for 
aerosolized liquid, -$98.4 for jet injection and +$3,959 for DNA vaccine).  This shows 
promise that an initial investment into research on a dry powder measles vaccine can result in 
a final product with a savings of $0.170 per dose, greatly improving the availability of this 
vaccine for mass vaccination campaigns. 
1.2 Vaccination by Inhaled Particles 
The lungs are well suited as a route of vaccination.  The human lungs have a high 
surface area, the average human alveolar surface area is 143±12 m
2
 (Garrison, Bauch et al. 
2011), and extensive vasculature.  The mucosal layer of the lung monitors inhaled antigens 
through the respiratory epithelium, alveolar macrophages and dendritic cells (Gehr, Bachofen 
et al. 1978).  When an antigen is identified, a cascade of signals results in the release of 
proinflammatory cytokines which promote inflammation and recruitment of additional 
specific immune cells, such as neutrophils, Natural Killer (NK) cells, monocytes and memory 
T cells (Kohlmeier and Woodland 2009).  After the initial defense against and clearance of 
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the antigen or infecting virus by naïve immune cells, antigen-specific T and B immune cells 
are converted to long-lived memory immune cells, capable of responding quickly to a 
secondary infection.  After the successful immune defense of the lungs a higher local 
concentration of memory T and B cells remain in the lung mucosal tissue (Piqueras, Connolly 
et al. 2006).  While the number of antigen specific memory T cells in the lung tissue 
normalizes to the systemic concentration after several months, antigen-specific memory B 
cells remain at a higher concentration in lung tissue, or site of infection.  These memory B 
cells localized in the lung tissue can respond quickly to a secondary infection and may secrete 
antigen -specific IgA, mucosa-specific immunoglobulin, to the mucous of the lung epithelia, 
leading to the immediate clearance or identification of infective agents (Kohlmeier and 
Woodland 2009).  There is additional evidence that the route of infection and initial immune 
response may result in improved immune response on secondary infection or even subsequent 
infections by a different agent (Liang, Hyland et al. 2001).  Initial infection of the lung may 
condition the local immune system, resulting in an improved heterologous immunity.   
Due to the possibility of improved immune response and inherent safety of needle-
free delivery, we have focused our research on developing vaccines delivered by inhaled dry 
particles.  In order to effectively deliver our vaccines to the lungs we must carefully control 
the physical properties and size of the particles.  The human respiratory system can be 
divided into the nasal-pharyngeal region, the upper airways, the lower airways and the 
alveoli.  Inhaled particles will deposit differently in each of these separate regions based on 
particle size, shape, mass and momentum (Figure 1.2.1) (Chen, Fraire et al. 2003).    
Inhaled particles larger than 10 µm in aerodynamic diameter (DA), defined as the 
diameter of the particle if it were to be a perfectly spherical particle and made of a material 
with a density of 1 g/cm
3
, generally deposit in the nasal-pharyngeal and upper airway regions 
due primarily to the impaction and interception methods of deposition.  These particles are 
usually removed to the digestive tract by swallowing.  At normal breathing rates (20 L/min) 
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and higher, particles with DA larger than 3 m deposit by the primary mechanism of inertial 
impaction in the tracheobronchial region (upper and lower airways), with increased 
deposition of the larger particles (Hinds 1999).  These particles deposit in the lung mucous 
and may be transferred by the mucosal elevator to the throat, where they will be transferred to 
the gastrointestinal system by swallowing.  Particles with DA values of 0.5 to 3 m can 
deposit in the tracheobronchial region but generally penetrate the upper respiratory system to 
deposit in the alveoli by diffusion.   
 
1.2.1 Figure deposition diagram 
Ultimately, particles below 10 m DA  reach the alveoli with varying amounts of 
attenuation due to deposition in the upper airways (Hinds 1999).  The particle size range 
generally chosen for deposition in the alveolar region is between DA = 1 and 5 m, where 
deposition in the upper airways is minimized but particles are likely to deposit and not remain 
in suspension to be exhaled.  Particles deposited in the alveolar region are not subject to the 
mucosillary elevator and have an increased residence time in the lungs.  The primary methods 
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of removal for these particles is by dissolution and transfer across the alveolar epithelia or by 
removal by macrophages or dendritic cells, which may result in an antigen-specific immune 
response.  In order to produce powders within this particle size, particle engineering must be 
employed to use the correct formulation and process parameters for optimal vaccine particles. 
Particle engineering is a relatively new area of research concentrating on the 
controlled formation of micro and nanoparticles for specific properties of size, shape, surface 
characteristics and internal composition (Hinds 1999).  Particles can be described by their 
geometric diameter (Dg), as determined by microscopy techniques.  A more valuable measure 
of particle size, for an inhaled pharmaceutical, is the aerodynamic diameter (DA), which takes 
into account differences in the momentum of particles caused by density variability.  The 
aerodynamic diameter of a spherical particle can be related to the geometric diameter by 
Equation 1. 
       √
  
  
       (1) 
Where P is the particle density and * is the unit density (1 g/mL) (Hinds 1999). 
Aerodynamic diameter is determined by analysis of the momentum of the particles, 
such as time of flight measurements and selective impaction or impingement methods.  These 
testing methods can be very dependent on the method of particle dispersion, as less powerful 
methods of dispersion may lead to the aerosolization of particle aggregates with larger 
observed DA values.   
 In spray drying, the aerodynamic diameter can be related to the concentration of the 
initial stock solution (CF) and the droplet diameter (DD) by Equation 2 (Chow, Tong et al. 
2007). This uses the assumption that the final particle is a solid, spherical particle. 
       √
  
  
 
√
  
  
  
 
   (2) 
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From Equation 2 it can be seen that initial droplet diameter is the primary deciding factor of 
the aerodynamic diameter of the dry particle with weaker relationships to stock concentration 
and particle density.  In order to optimize the particle size, many methods decrease the stock 
concentration (as low as 0.01%).  This increases the ratio of water/solvent to solid material 
which can result in high residual moisture in the dried particles and will require additional 
drying energy and temperatures, compared to higher stock concentrations, which may 
decrease the activity of thermally sensitive active ingredients.  Higher concentrations (our 
standard concentrations are 10% mass/volume) produce more product for a given spray flow 
rate and have lower solvent removal energy requirements.  Higher concentration feed stock 
can result in larger final particles, due to larger amounts of solute in the individual droplets, 
but particle size can be reduced by decreasing the size of the droplets with more energy added 
at atomization.  For most methods of spray drying, scale-up can be more readily achieved 
with increasing the flow rate rather than greatly increasing the concentration.  We have 
observed decreased particle sizes with lower concentration, but the relationship between 
aerodynamic diameter and concentration is complicated by the additional relationship 
between droplet size and solution viscosity/surface tension. 
 In a drying droplet, not all components will behave the same and component 
enrichment of the surface or core of the particle may occur (Vehring, Foss et al. 2007; 
Vehring 2008).  In a drying spherical droplet, the surface enrichment (Ei) of component i, or 
the ratio of its concentration on the surface (cs,i) to its concentration in the droplet bulk (cm,i) 
can be estimated by Equation 3 (Vehring 2008). 
       
    
    
 
         
   
  (3) 
Where βi is a function dependent on the Peclet number (Pe) and the Peclet number is a 
dimensionless value descriptive of the relative mobility of the component i in the drying 
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solution.  The Peclet number can be calculated based on the evaporation rate (κ) of the 
droplet and the diffusion rate for component i (Di), Equation 4 (Vehring 2008). 
        
 
   
   (4) 
The diffusion rate for a given solute component in a drying droplet is heavily reliant on the 
size of that component.  Large or insoluble molecules will have mobility in the feed solution 
compared to the evaporation rate for the droplet and thus will be “gathered” by, or 
concentrated on, the inward moving surface of a drying droplet.  As the droplet shrinks and 
the surface area decreases, the material enriched on the surface may reach sufficient 
concentration to form a solid shell.  The remaining solvent, with the remainder of the 
dissolved components, will continue to evaporate inside this outer shell.  Depending on the 
diffussability of the vapor through this shell, the particle may burst to release the vapor, or 
allow the vapor to pass through the shell, creating a hollow or porous particle with a density 
lower than the bulk material.  Some formulations intentionally include surface active 
(Vehring, Foss et al. 2007) or slowly diffusing nanoparticles (Vehring, Foss et al. 2007) to 
intentionally form large porous or hollow particles.  Hollow particles can be beneficial to 
inhalable formulations as they may require less energy to disperse and may have the DA 
sufficient to reach the deep lung but a Dg that is too large to allow phagocytosis by 
macrophages in alveoli, will result in an extended lifetime in the lungs (Vehring, Foss et al. 
2007). 
 
1.3 Spray Drying 
 Spray drying has been studied since the 1860s, but was extensively modified and 
improved during World War II with efforts to transport large amounts of foodstuffs over 
great distances (Lechuga-Ballesteros, Charan et al. 2008).  In general use, such as the 
production of powdered milk and other food stuffs, spray drying removes most of the water 
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from an aqueous solution or suspension of the material of interest.  The dehydration of the 
material reduces the potential for microbial activity, increases the product stability and 
reduces the weight and volume of the final product (Tsapis, Bennett et al. 2002).  The 
reduction of a material to small particles with large surface areas may also be desirable to 
increase the rate of dissolution of lower solubility materials (Tsapis, Bennett et al. 2002).  
Spray drying is the conversion of a fluid feed material to particulate form through the 
introduction of droplets of fluid feed into a gaseous medium.  The spray drying process can 
be divided into three separate phases: atomization, drying in a gaseous medium and product 
collection. 
1.3.1 Subsection 1.3.1 Atomization 
 Atomization is the process of forming a dispersion of the feed stock fluid in a 
gaseous medium.  The fluid feed stock may consist of a solution or suspension of the material 
of interest in any fluid solvent or a fluidized or molten form of the material of interest.  The 
most common earlier methods of atomization are: rotary, hydraulic nozzles, pneumatic 
nozzles and ultrasonic nozzles (Tsapis, Bennett et al. 2002).  
 Rotary nozzles use centripetal forces to produce an atomized spray of the feedstock.  
This is achieved by running the liquid feedstock over a spinning surface; spray is produced 
when the liquid is flung from the edge of the surface.  This process is used for large scale 
spray drying and is easy to scale up, but produces large droplets, not conducive to obtaining 
final dried particles in the inhalable size range.   
 Hydraulic nozzles produce droplets by forcing a pure liquid feedstock through an 
orifice, as a jet, at high pressures/flow rates.  Liquid break-up when exiting a jet can be 
described based on the dimensionless number Z’ (The ratio of the Weber/Reynolds numbers). 
       
 
       
 
 ⁄
   (5) 
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Where 1= liquid density, dn=jet diameter, σ=surface tension and µ=liquid viscosity.    The 
ratio of the Z’ number  of a jet to the Reynolds number of the jet can describe the break-up 
pattern of the liquid exiting the jet with complete atomization occurring at high values of this 
ratio (Cal and Sollohub 2010). A low viscosity feedstock is required for this method and the 
final dried particles are usually in a broad size range, well above the desired size range for 
inhalation (Jangam 2011). 
  Pneumatic nozzles, or multi-fluid nozzles, operate by combining the liquid feedstock 
with a carrier gas.  The friction between these two fluids causes the liquid disintegration of 
the feedstock.   The mean droplet size (DDM) produced by this method is very complex but 
can be approximated by Equation 6 
        
 
          
  (
    
    
)
 
 (6) 
Where A,B, α and β are variables dependent on nozzle design and liquid properties, Vrel is the 
relative velocity between air and liquid at the orifice, a is the density of the air and Mair/Mliq 
is the mass ratio of air to liquid (Srinarong, de Waard et al. 2011).  From this it can be seen 
that for higher flow rates of carrier gas, smaller droplet size can be achieved.  The air can be 
introduced to the liquid before or, more commonly, at the exit of the nozzle (Cal and 
Sollohub 2010).  A wide variety of intricately engineered pneumatic nozzles have been 
produced to control the size range of droplets in the spray.  Currently, pneumatic nozzles are 
the most common form of atomization used for the production of inhalable pharmaceutical 
particles.   
 Other variants of atomization exist, but are less common due to lack of 
characterization and lower efficiencies.  One such method, supersonic atomization, uses a 
high frequency electrical current placed over a nozzle made out of a piezoelectric material to 
induce supersonic vibrations. The liquid stream exiting the nozzle is disintegrated based on 
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the frequency of these vibrations (Masters 1972).  This provides a very controlled source of 
droplets in a narrow size range but is difficult to scale-up for industrial production. 
 Our research concentrates on the atomization of the feedstock liquid by the carbon 
dioxide assisted nebulization with a bubble dryer (CAN-BD) process.  The method of 
atomization is a variant of pneumatic atomization, where, instead of a low pressure 
nebulizing gas, a highly pressurized, near critical gas (generally carbon dioxide) is mixed 
with the liquid before exiting the nozzle.  The nozzle used is exceedingly simple, a small (75-
µm or 100-µm) tube made of fused silica or stainless steel, which distinguishes this variant 
from other forms of high pressure atomization.  The high density of the pressurized gas 
increases the Mair in Equation 4, which allows for increased mass flow rates of the stock 
without significant increase in droplet diameter.  The mixture of the atomizing gas and stock 
is achieved by directly opposing flow in a low volume mixing tee.  During this mixing, it is 
hypothesized that the high pressure gas partially dissolves into the stock solution (up to 6% 
by mass), which creates a near saturated solution when the droplet is returned to atmospheric 
pressures as the spray is directed into the drying chamber.  The rapid dissolution of the 
dissolved gases, and evoltion upon decompression, results in the fragmentation of liquid 
bubbles in the spray, further decreasing the average size of the droplets.  Additionally, the 
rapid expansion of the near critical gas adds frictional forces to the liquid spray, causing 
additional liquid fragmentation.  The benefit of small initial droplets is that less total heat is 
required to dehydrate the droplets and the final dry particles result in accordingly smaller 
particles.  Atomization using the CAN-BD process has been shown to readily produce 
droplets which, upon drying, form particles with mean DA values in the respirable range (5 
µm to 1 µm).  
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1.3.2 Powder Drying  
 Drying of the atomized feed stock is achieved by exposing the dispersion to a 
gaseous media of low humidity.  The most common drying gasses used are 
conditioned/heated environmental air or warmed or heated dry nitrogen gas, if an inert 
environment is desired.  Each droplet in a spray is exposed to different local drying 
conditions due to its differences in the turbulence and flow of the drying gas and the local 
changes due to the drying of neighboring particles (Cal and Sollohub 2010).  Optimization of 
the drying process generally focuses on the average drying conditions of the largest droplets, 
which will be the slowest to dry, and represent a larger mass of the final product, which may 
adversely affect the smaller dry particles upon co-collection.  The drying conditions are 
controlled by drying chamber geometry and drying gas flow rate and heat.   
Different drying chamber geometries can result in differences in droplet residence 
time, air exposure and turbulent mixing.  The primary types of drying chambers are 
concurrent, where the aerosol spray and drying gas flow in the same direction; counter-
current, in which the spray and drying gas flow in opposite directions; and mixed flow dryers, 
where spray flows against and with drying gas in two separate phases.  Concurrent flow can 
result in lower residence time, but droplet-droplet interactions are minimized.  Counter-
current chambers have larger droplet residence times, but require heavier droplets/low drying 
gas flow rates to separate the product from the drying gas flow.  Mixed flow chambers result 
in longer residence times and increased drying gas exposure due to turbulent mixing in the 
drying gas, but also increase the risk of droplet-droplet interaction and aggregation by mixing 
the drier particles with newly-sprayed wet droplets (Masters 1972).   
Drying gas flow rate and temperature can be adjusted more readily than other spray 
drying parameters and are usually chosen as the primary parameters for drying optimization.  
These parameters can be monitored by the flow rate and temperature (inlet temperature) of 
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the gas into the chamber and the temperature of the exiting gas (outlet temperature).  The 
flow rate of drying gas determines the residence time of the droplets and the turbulence of the 
drying gas in the chamber, Equation 7. 
                                                  ⁄   (7) 
The Reynolds number (Re) for flow in a pipe is a unit-less number that can be calculated 
using the velocity of flow (u), hydraulic diameter of the pipe (dh), or drying chamber, and 
kinematic viscosity of the fluid (ν), or drying gas.  For Re < 2300 flow will be laminar, 2300 
< Re < 4000 flow will be transient and Re > 4000 flow is considered turbulent.  Particles 
entrained in a laminar flow can remain separated from neighboring particles and are less 
likely to aggregate but solvent exchange with the gas may be limited by a boundary layer.  
Particles entrained in a turbulent flow will be at a greater risk of impacting with other 
particles and onto the dryer surface, but will have a smaller boundary layer and greater 
solvent exchange with the drying gas.  These conditions are highly variable with the variant 
of spray drying used and the desired effect.   
 Inlet and outlet temperature can be controlled to affect the drying rate and final 
particle properties (Cal and Sollohub 2010).  Increased inlet temperatures can increase the 
evaporative capacity of the dryer and may result in the formation of lower density, hollow or 
porous particles and particle component inhomogeneity due to the rate of droplet evaporation 
(Cal and Sollohub 2010).  Inlet temperature is controlled by preheating drying gas through 
heat exchange.  Outlet temperature can be controlled by adjusting feed flow rate.  By adding 
additional atomized solution to the drying gas, more of the heat of the drying gas will be 
absorbed by the liquid in the spray as the heat of vaporization, resulting in a lower outlet 
temperature.  Due to evaporative cooling, particles that still contain solvent at the outlet may 
be cooler than the surrounding air. Dry particles, however, will have the same temperature as 
the surrounding air (outlet temperature).  The outlet temperature is representative of the 
highest possible temperature of the particle exiting the drying chamber.  This variable needs 
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to be controlled to prevent thermal degradation of the dried material and should be kept as far 
as possible from the glass transition of the final powder to prevent loss due to powder 
stickiness (Masters 1972).   
 The CAN-BD process used in our research uses a 1.5 L glass conical, concurrent 
drying chamber.  Dry nitrogen gas is heated by an in-line thermal transfer element and 
introduced to the spray at a typical rate of 30-40 L/min (giving an average residence time of 
3-2.5 seconds).  Some turbulence is noted, as there is seen adhesion of powder uniformly on 
the internal glass surface of the drying chamber, which may indicate a higher residence time 
for the drying particles.  Inlet air temperature is controlled, by adjusting the voltage supplied 
to the heating element, to produce outlet temperatures from 50 to 80 °C.  Drying under lower 
outlet temperatures decreases the exposure of the powder and active ingredients to the 
possibility of thermal degradation.   
1.3.2 Particle Collection 
After the initially atomized droplets are dried into dry particle form the particles need to be 
collected through separation from the drying gas.  The most common methods of separation 
are through filtration, inertial separation in a cyclone, or electrostatic separation (Masters 
1972).  Filtration is the simplest and most efficient form of separation.  In filtration 
collection, particles are transferred from the drying gas to the surface of a filter by passing the 
drying gas with suspended particles through a filter with pore size smaller than that of the 
particles.  Filters may be porous material due to interlocking fibers, sintered materials or 
etched cylindrical pores and may be placed as a terminal surface or as a collecting bag 
(Masters 1972).  Material can be collected at intervals by intermittent removal from the filter, 
or continuously, in the case of back-flow bag filtration, through bursts of counter current air 
with collection by deposition into a removable reservoir (Vehring, Foss et al. 2007).  
Separation by cyclone involves sending the particle laden exhaust air in a spiral pattern down 
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and then up a conical cyclone collection device, eventually leaving through the top.  Particles 
with sufficient inertia will impact on the walls of the cyclone device and fall or slide down to 
the collection chamber below.  This method is commonly used due to its simplicity, 
continuous operation and ease of powder removal.  One notable difficulty with this method of 
separation is that particles with very low inertial (such as particles below 10 µm in DA) are 
not efficiently separated using normal flow rates and can remain suspended in the vented 
exhaust air (Truong, Bhandari et al. 2005).  Another effective method of particle removal is 
electrostatic precipitation, where suspended particles receive a static charge and are removed 
from the air flow by applying a voltage over the airflow directed towards collection plates.   
 Dried powders produced by the CAN-BD process are collected on “dead end” 
membrane filters.  Air flow is directed over the surface of a membrane filter where entrained 
particles are removed.  These particles may be exposed to additional heated drying air after 
the spray has been stopped, through a secondary drying process.  Particles are collected either 
by scraping off the filter at the end of a run or through continuous collection by an engineered 
dual filter system.   
 Once powders have been collected it is necessary to store the particles under 
conditions that will not compromise their activity or physical properties.  Our group has used 
sealed glass screw top vials, plastic vials and various aluminum foil/polymer laminate film 
materials as high barrier overwrap packages containing packets or “pillows” of molecular 
sieves or other desiccants.  Our primary method of storing bulk powder is in a closed glass 
screw top vial with Teflon liner, heat-sealed inside an aluminum-based laminate overwrap 
material with packets of desiccant material, usually molecular sieves.  This prevents moisture 
ingress into the powder and possible degradation due  hydrolysis, oxidation or exposure to 
light.  With our collaborators at Aktiv-Dry LLC, we have also designed single dose particle 
storage containers consisting of mold-formed plastic backing with a recessed slot to hold the 
powder and covered by a peelable aluminum foil strip heat sealed to the backing.  This allows 
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for simple loading of a single dose into the Aktiv-Dry/CU-designed PuffHaler dispersal 
device for delivery of the dry powder aerosol vaccine. 
1.4 Inhaled Powder Product, Dispersal and Delivery 
 There are many available dry powder inhaler (DPI) devices available on the market, 
but most of these are “passive”, requiring the patient to inhale forcefully upon command.  
“Active DPI devices” provide  the addition of external forces to disperse the powder as an 
aerosol for a patient to inhale, while powder in passive devices typically must be dispersed as 
aerosols by the breathing of the recipient, who must be old enough, and well enough to inhale 
aggressively.  As our primary goal for measles vaccination is infants, who cannot be 
depended on to breathe on command, we designed an active delivery device, called the 
PuffHalers.   
The major factor in the efficiency of a DPI is its capability of powder dispersal.  The 
bulk stored particles for delivery are in direct contact with each other and require additional 
external energy to break up the aggregates into individual particles for inhalation.  There are 
many different possible methods of dispersal used with different DPIs, including pressurized 
air from pumps or contained gas, sonic dispersion and electrostatic dispersion.  In order to 
remove the need for an electrical power source, often an  unavailable luxury in underserved 
areas where vaccination is most needed, our group designed, and tested a hand-powered air 
bulb for powder dispersal in the PuffHaler.  When squeezed, the hand powered bulb releases 
air at a pressure controlled by the opening of a tetrafoliate pressure-release valve.  This 
pressurized puff of air is sufficient to disperse and aerosolize vaccine powder from the 
opened powder container placed in the molded plastic PuffHaler device.  The powder-laden 
air inflates an anti-static reservoir bag, with attached mask, which can be placed over the 
mouth and nose of the recipient for delivery to the lungs by at liberty breathing.   
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The PuffHaler device has been shown to deliver our powders effectively to the lungs 
of cotton rats (Masters 1972) and rhesus macaques (Hinds 1999) through at-liberty breathing.  
The device was also designed with reusable components and inexpensively produced 
disposable components, resulting in a total cost per delivered dose of ~ $0.10, for the delivery 
system, which is comparable to the cost of vaccine delivery by injection with needle and 
syringe. The cost of  the stabilizing sugar, myo-inositol, used in the inhalable dry powder 
measles aerosol vaccine to replace the sorbitol used in the present commercially available 
lyophilized measles vaccine, is not expected to add significantly to raw materials costs, so the 
new vaccine with the PuffHaler, or with BD-Technologies’ Solovent DPI, following human 
clinical trials, should be comparable in price to the EZ measles vaccine product sold by the 
Serum Institute of India in 127 countries throughout the world.  
1.5  Research Objectives 
 Through the design and production of an inhalable dry powder measles vaccine we 
have developed a safe and effective alternative measles vaccination to traditional delivery by 
injection.  In the design of this final product, extensive research was conducted on optimizing 
production parameters and formulation.  Characterization was conducted on the feed material 
and resulting powder, throughout subsequent packaging and during stability tests.  This 
characterization revealed variances in placebo material and helped to better understand the 
stability of the physical and chemical properties of the vaccine powder. 
A powder was designed and produced to study the toxicity of a novel inhalable 
excipient, myo-inositol.  The processing and characterization of pure myo-inositol powders 
revealed an anhydrous metastable crystal polymorph of myo-inositol which was formed under 
specific process variables.  Due to its metastable nature this polymorph is to be avoided in 
particle production but this method of producing a relatively pure form of a unique 
polymorph may provide additional insight into the chemical properties of myo-inositol. 
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 In order to provide an alternative to the currently commercially available liquid HPV 
vaccine, a dry powder protein subunit Human Papilloma Virus vaccine was designed and 
produced.  This dry powder vaccine shows no evidence of protein degradation during 
processing and retains the HPV16 L1 protein conformation required for antigenic activity, as 
determined by ELISA testing.  This powder has been delivered to Sprague Dawley rats by 
insufflation, reconstitution with alum adjuvant and injection and sublingual pellet with no 
adverse reactions.  Immunogenicity results are forthcoming, but not available at the time of 
the writing of this dissertation. 
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________________ 
Chapter II Methods 
________________ 
2.1 Powder Preparation and Processing 
All powders were produced using the Carbon Dioxide Assisted Nebulization with a Bubble 
Dryer (CAN-BD) process.  All vaccine powders were prepared inside a LABCONCO Purifier 
Class II Biosafety Containment Cabinet Delta Series using a Bubble Dryer Model #BD-1000, 
Temco Instruments, Tulsa OK for liquid and gas control and monitoring.  Pump and 
temperature data were recorded using the Temco Instruments  Smartdry -2© v1.01 program.  
Carbon dioxide flow rates, density and temperature were monitored by a Micro Motion Mass 
Flow Meter and recorded by the Prolink II v2.6 Software. Standard operating parameters 
were as follows.  CO2  pressure was set to 1200 psi, and CO2 pumps were temperature 
controlled (25°C to 30 °C)  by a Thermo Electron Corporation Neslab RTE 7 heat exchanger 
circulating ethylene glycol.  The aqueous solution or suspension flow rate was set to 0.3 
mL/min to 2 mL/min. Solutions were prepared from 1 % to 20 % (total dissolved solute by 
mass) with 18 M water from a Barnstead Nanopure Diamond water purifier.  The Nitrogen 
drying  gas flow rate was set at 30-40 L/min through the Pyrex glass drying chamber  and 
heated to 40-80 °C.  The regulator pressure was set to 30 to 60 psi.  The solution of interest 
was nebulized through a 10 cm long, 75 m ID silica restrictor (Polymicro Technologies 
LLC Part # 2000019).  For powder production runs of 2 g or less, the dry product was 
collected on a dead end filter (MAGNA, Nylon, Supported, Plain 0.45 Micron 142 mm 
Diameter, GE Water and Process Technologies) inside a stainless steel filter assembly.  
Powder was collected from the filter using a stainless steel spatula after the run.  Larger 
processing runs were collected on a dual filter, back-pulse system designed by David Krank 
at Aktiv-Dry.  In the dual filter back pulse-system, the drying chamber exit gas flow was 
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directed through a 90 degree glass elbow; some additional loss was noted due to particle 
inertial impaction in the area of this change in flow.  The dual filter back-pulse assembly was 
observed to have lower temperatures ( 30 to 40  °C ) than the outlet temperature exiting the 
drying chamber (60 °C ).  The filters used in the dual back pulse system were MAGNA, 
Nylon, Supported, Plain 0.45 Micron 142 mm Diameter, GE Water and Process 
Technologies.  When using the dual filter back pulse system, powder was periodically cleared 
from the primary filter (top) and dropped to the collection filter (bottom) using 5 bursts of 15 
psi dry nitrogen every 10 minutes.  These pulses transferred dry solid collected on the top 
filter to the bottom filter, where additional drying gas was passed through the powder at 15 
L/min to provide additional drying ( moisture content for the measles vaccine was usually 
0.5% to 2% water by mass using this method).  Powders were collected directly from the dual 
filter back pulse system into a sealable glass jar. 
Powders were stored in clean glass or plastic vials stored in high barrier aluminum 
foil-polymer laminate overwrap with molecular sieve desiccant pillows (Desiccare Inc. 0.5 g 
Molecular Sieve Pak). Temperature sensitive powders were stored in a refrigerator 2 to 8 °C.  
Temperature was monitored continuously using Thermocron or Hydrochron iButtons.  
Materials with active ingredients (measles vaccine, protein or unstable crystal structure) were 
stored strictly at 2-8 °C, to prevent degradation.  Placebos and non-active powders could be 
stored at room temperature without any observed detrimental effects. 
2.2 Andersen Cascade Impaction  
There are a variety of methods available for the analysis of geometric particle 
sizesincluding analysis of electron microscopy images, light scattering and sieving methods. 
Geometric particle size may not be the best representative variable when analyzing the 
dynamics of inhaled particles.  A better measure of the potential particle performance is the 
aerodynamic diameter, which separates particles based on their behavior when entrained in a 
  
26 
 
laminar flow, as compared to a model particle that is perfectly spherical with a unit density of 
1 g/cm
3
.  A variety of methods are available to assess the aerodynamic diameter of particles 
using time-of-flight or inertial impaction in to a liquid (impingers) or onto a series of plates 
(cascade impacters).  As our powder was intended for the delivery of a live-attenuated virus 
in a complex formula, we required an analytical method that was portable enough to fit in the 
biosafety containment cabinet, easy to clean thoroughly and did not require extensive 
chemical analysis of new formulation constituents.  Andersen Cascade Impaction is a 
common method of aerodynamic diameter determination of inhaled pharmaceuticals and is 
specified in the US Pharmacopoeia.  Most of the particle size analysis performed by our 
group was conducted using a four- or eight- stage Andersen Cascade Impactor with 
gravimetric analysis. 
2.2.1 Four-Stage Andersen Cascade Impaction 
  
Particle size in the respirable range was observed using the modified Westech 8-stage 
Non-Viable Cascade  impactor (Andersen Cascade Impactor or ACI).  All weighing of 
hygroscopic materials was conducted a dry environment controlled to have a RH <15%.  
Before assembly, a pre-weighed glass fiber filter (Pall Life Sciences A/E Glass 81 mm) was 
placed in the F stage and held in place by a silicone polymer ring.  Another pre-weighed filter 
was placed on a plate with its lip oriented upwards, the plate was placed on top of stage F.  
The stages F, 3, 1, and 0 and the neck of the instrument were assembled on top of the base 
and a solid plate was placed between stages 3 and 1 and a plate with a central hole was placed 
between stage 0 and stage 1.  The springs were set to seal the system and the base was 
connected to a vacuum pump (Figure 2.1).  If the RH of the room was above 15%, the tests 
were conducted inside a dry box dried to no more than 15% RH with dry nitrogen.  In 
common operation, an Aerolizer® Inhaler Demonstration Unit (Schering Corporation) and a 
gelatin capsule were used for powder dispersal.  The gelatin capsule was filled with 8-12 mg 
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of the powder of interest; filling was conducted in a dry box when the room humidity was 
above 15%.  The capsule was shocked five times over five seconds using a “static gun”, 
which helped to discharge static charge build up in the powder  which was then placed in the 
Aerolizer.  The Aerolizer capsule puncture needles were compressed to puncture the capsule 
ends and the Aerolizer was then closed.  The vacuum pump attached to the ACI was turned 
on and a flow meter was used to ensure that the flow rate was 28.3 standard liters/minute, as 
specified by the USP and manufacturer protocol.  Previous tests ensured that the pressure 
drop of the ACI was at least 4 Kpa.  The Aerolizer was placed in the ACI  neck inlet and the 
connection was sealed by a rubber stopper.  While the Aerolizer was in contact with the ACI, 
it was ensured that the capsule was rattling inside; if the ratting stopped, the capsule was 
reseated and then returned to testing.  After pulling air through the Aerolizer for eight 
seconds, the Aerolizer was removed and the vacuum pump was shut off.  In some cases the 
BD Solovent or Aktiv-Dry PuffHaler
TM 
 (Figure 2.2.1) were used for powder dispersal.  In 
these cases, prefilled capsules or foil packs were actuated using the proper dispersing method 
and the powder bolus was either introduced directly to the inlet of the ACI or through the 
evacuation of the PuffHaler aerosol reservoir bag (made of an antistatic polymer material) or 
the Solovent spacer box.   
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2.2.1 Figure- PuffHaler and component parts 
The empty capsule, the filter in stage F and the filter under stage 3 were weighed.  
The mass of powder on the stage F filter (MF) was the mass below 3.3 m in aerodynamic 
diameter and the sum of the masses on stage F filter (MF) and Stage 3 filter (M3), compared to 
the mass of powder loaded into the device (ML), gave  the mass below 5.8 m in 
aerodynamic diameter.    Powder was characterized by %< 3.3 m by Equation 2.1 and % < 
5.8 m by Equation 2.2.  The value of % < 5.8 m was considered the respirable (inhalable) 
fraction. 
 
    
  
  
                   (2.1) 
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Figure 2.1 Four (left) and eight (right)-stage Andersen Cascade Impactors 
 
2.2.1 Eight-Stage Andersen Cascade Impaction 
In order to analyze the powder using a larger number of size bins, the 8-stage 
Andersen Cascade Impactor assembly  was used.  The United States Pharmacopoeia (USP) 
method 601 was followed.  This was conducted in much the same way as the 4-stage device 
arrangement using the ACI with stages F, 8 through 0.  Gravimetry was used with this 
method.   Additional chemical methods were occasionally used to improve sensitivity and 
validate the analysis.  As only a maximum of 1 or 2 mg of powder were expected to deposit 
on the metal stages of the ACI, a much more sensitive technique, Total Organic Carbon 
(TOC) analysis, was employed instead of gravimetric analysis when necessary (Masters 
1972).   
The procedure laid out by Rebits et al called for an extensive cleaning procedure to remove as 
much organic carbon as possible with ultrapure water.  All materials were allowed to dry and 
were assembled on clean aluminum foil.  The plates were coated with a thin layer of Dow-
Corning silicone grease and the ACI was assembled.  After the powder was aerosolized into 
the device according to the previously mentioned gravimetric method, the device was 
carefully disassembled and rinsed with ultrapure water.  The water samples were transferred 
to clean TOC vials and tested for TOC and Inorganic carbon using a SIEVERS® Model 800 
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Total Organic Carbon Analyzer  with a SIEVERS® Model 820 Automatic Sampler (both 
from GE Analytical Instruments, Boulder, CO). 
2.3 Emitted Dose Device 
 
 In order to obtain emitted dose data for individual powders using a designated Dry 
Powder Inhaler (DPI), the amount of powder deposited on the filter from dispersing into a 
standard emitted dose device was determined.  A 46-mm glass fiber filter was weighed and 
placed in a USP emitted dose device.  The device was connected to a vacuum pump and air 
was pulled at a flow rate of 28.3 Standard L/min.  The DPI of interest was actuated to 
disperse the aerosol into the opening of the emitted dose device.  The weight of the powder 
on the filter with deposited powder was divided by the loaded mass to determine the percent 
emitted dose. 
2.4 Model DP-4 Dry Powder Insufflator (PennCentury) 
 
 The dry powder insufflator for rat studies was tested using the ACI and the Emitted 
Dose Device.  The powder reservoir of the insufflator was filled with 5-10 mg of powder and 
sealed. The mass of the powder added was determined be the difference in the weight of the 
empty insufflator and the filled insufflator.  A 3-ml syringe was used to dispense 0.5-2 ml of 
air to aerosolize the powder into the mouth of the running ACI or Emitted dose device.  For 
each actuation, only 2-3 mg of powder was aerosolized.  In order to get enough powder to 
reliably determine the particle size or emitted dose, several (3-5) actuations were conducted 
and the final result was the average of these replicates.  Testing of powder dispersed using the 
insufflator may not be fully represented by the ACI results, as additional momentum is 
supplied to the powder through the dispersal air.  A significant amount of powder was noted 
to have impacted on the angle change at the end of the neck portion of the ACI.  In general, 
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dispersion of powder using the Insufflator device resulted in observed FPF values equal to or 
greater than those observed for the same powders using the Aerolizer as a dispersal device.    
2.5 Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) analysis on powders and dry bulk material 
was conducted using a Perkin Elmer Diamond DSC.  Samples (1-10 mg) were loaded into 
aluminum DSC sample containers in a dry environment (15% RH) and hermetically sealed.  
Sample containers were placed in the sample pan of the DSC with an empty sample container 
placed in the reference pan.  The DSC was controlled by Pyris software.  Samples were 
generally analyzed using a heating rate of 100 °C/min to maximize signal.  The samples were 
cooled to –20 °C, or well below the potential zone of interest for the material.  Samples were 
heated beyond the area of interest at 100 °C/min and then cooled at 100 °C/min to the starting 
temperature and allowed to equilibrate for 2 minutes.  The sample was then heated a second 
time past the temperature zone of interest at 100 °C/min.   
 The data from the first scan was recorded as the thermal profile of the processed 
material, while the second scan was recorded as the thermal profile of the bulk material, 
assuming the initial scan was not chemically destructive to the sample.  In the case of a 
powder, the first scan is the thermal profile of the individual particles in aggregate as they go 
through the glass transition or melting point and lose their physical powder properties and 
spread out over the bottom of the sample container.  The second scan represents the thermal 
profile of the bulk material spread out over the bottom of the capsule.  In general, the glass 
transitions observed in first scans are at lower temperatures than the glass transitions of 
second scan and first scans generally have larger exothermic overshoots than the second 
scans.  This represents the thermal properties and artifacts of the particles vs. the bulk; 
particles have much larger surface area and are more affected by the heat transfer.  The larger 
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exothermic overshoot is due to the energy associated with the particle melting and fusion and 
is not as pronounced in the bulk.   
 Glass transitions were identified by S-shaped slight inflections of the heating curve 
and were analyzed by Pyris software.   Tg Onset (°C), Half Cp extrapolated (°C) and Cp 
(J/g °C) values were reported and used for powder comparisons.  Melting points were 
identified by large exothermic peaks in the heating curve.  Melting points were analyzed by 
the Pyris software and Onset, midpoint and peak height or area were recorded.  
Crystallization events were observed as exothermic events on the heating or cooling curve 
and analyzed by the Pyris software.  The cooling curve data was not used for analysis as the 
instrument did not regulate the cooling stage in an analytically reliable manner . 
2.6 Karl Fischer Titration Moisture Analysis 
 
Powder and bulk solid moisture content was determined by Karl Fischer moisture 
analysis.   Powder or bulk solid (10-100 mg) was transferred into clean/dry 1 dram vials in a 
dry environment (no greater than 15% RH).  About 1-2 ml of dry methanol (at most 0.3% 
water by mass) was added to the powder in the vials. The vials were sealed, mixed 
thoroughly on a vortex and centrifuged to remove the suspended powder to a pellet.  The 
humidified methanol was removed through a syringe and injected into a Denver Instruments 
Model 260/275 KF Coulometric Karl Fischer Titrator using Riedel-de Haen Hydranal-
Coulomat AG and Hydranal Coulomat CG Catholyte.  Moisture content was reported and 
compared to the injected methanol mass and powder mass to determine the total moisture 
content of original powder.   
2.7 Powder X-ray Diffraction 
 
Powder X-ray diffraction (XRD) was conducted on the powders to determine 
crystallinity, compare with literature XRD patterns and identify significant peaks.  Powder or 
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bulk solid material was placed in a thin layer in an acrylic sample cuvette.  The sample 
cuvette was placed into the rotating sample holder of a SCINTAG PAD-5 XRD instrument 
and analyzed from 2Theta= 5° to 45° at a scan rate of 2°/sec.  The Instrument used a Cu K-
alpha source set to 1.540562 Å.  The powder was determined to be amorphous if no clearly 
visible peaks appeared above the acrylic holder background or an amorphous hump was 
observed.  A sample was determined to have some crystalline characteristics when visible 
peaks were observed.  Peaks were identified and evaluated by comparison with an 
International Center for Diffraction Data (ICDD) database. 
2.7 TSI Aerosizer 
 
In the initial stage of this research, the TSI Aerosizer was used to assess the 
aerodynamic particle size range.  Powder (about 10 mg) was placed in the sample cup of the 
TSI Aerolizer 3225 with a 3230 Aero-Disperser and the sample run was controlled by the 
standard TSI software.  Powerful bursts of air were used to fully aerosolize and disperse the 
powder.  Powder sizes were determined by time-of-flight between two light sources. The data 
produced by this instrument represented the ideal particle size range of the powder, different 
values are expected for less powerful dispersion methods such as ACI with the Aerolizer, 
PuffHaler and Solovent due to particle cohesion and adhesion from static forces, stickiness 
and Van der Walls forces.     
2.8 Scanning Electron Microscopy (SEM) 
 
  Early SEM pictures were taken at the Laboratory for Environmental and Geological 
Studies in the CU Geology Department.  Powders were taken to the microscopy facility in a 
sealed container over molecular sieves on conductive tape on aluminum SEM stubs.  Care 
was taken to spread the powder into a thin layer to allow the electrons to pass through the 
sample to the tape and minimize sample charging.  The powders were gold sputter coated at 
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the Geology facility and placed in the JEOL ISI SX30.  Pictures were taken at 5-30 KeV and 
recorded on film.  Pictures were later converted to digital images with a scanner and 
processed by Photoshop software. 
 Later SEM pictures were taken with a low vacuum SEM (LVSEM), JEOL-6480LV, 
at the Nano Characterization Facility in the CU Discovery Learning Center.  A thin layer of 
sample was spread onto conductive tape on an SEM stub in a low humidity environment (less 
than 15% RH) and the samples were transferred in a dry desiccator to the facility.  Samples 
were placed into the LVSEM sample chamber, a vacuum was applied to reduce the pressure 
to 1-10 Pa, and images were captured using 5-30 keV accelerating voltage.  This instrument 
was designed to image materials that are prone to charging and well-resolved images were 
obtained without gold coating of the particles and materials.  If particles were observed to 
melt under the electron beam or minor charging was noted, the voltage of the instrument was 
reduced.  Highly charged aggregates of particles were avoided in favor of well-dispersed 
particles in direct contact with the conductive tape. If excessive charging was observed (i.e., 
moving particles, intense or changing contrast) a new image was obtained using gold-coated 
particles.  Digital copies of the pictures were saved and processed by Photoshop software. 
 
References for Chapter II 
1. Rebits, L. G., D. J. Bennett, et al. (2007). "Method for quantifying the sample collected by 
an Andersen Cascade Impactor using total organic carbon analysis." Journal of 
Aerosol Science 38(12): 1197-1206. 
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________________ 
Chapter III Characterization of a Dry Powder Measles Vaccine 
________________ 
3.1 History of Measles 
Measles, originally known as “Rubeola” in the middle ages, is an RNA virus of the 
Morbillivirus and Paramyxoviridae family that has been documented in humans since at least 
the seventh century (Masters 1972).  Infection with the measles virus begins with symptoms 
such as cough and fever followed by a maculopapular rash and small red-rimmed white dots 
(Kolik’s spots) on the mucous membrane of the oral mucosa.  Measles may result in diarrhea, 
pneumonia or encephalitis in children, with greater severity and danger in younger children.  
Measles is an incredibly contagious disease with an estimated infection rate of at least 95% 
(Kisich, Higgins et al. 2011) and was once considered an unavoidable childhood ailment.  A 
2004 WHO study estimated that, globally, 424,000 deaths were caused by measles directly or 
indirectly that year, most of these deaths occurred in the low and middle income populations 
of Africa and South East Asia (Lin, Griffin et al. 2011).  This study also estimates that, 
despite the existence of an effective vaccine, measles directly causes up to 4% of all deaths in 
children under 5 years of age.  This puts measles as the leading vaccine preventable 
childhood disease and shows the disproportionate burden that it puts on the developing world.  
In order to reduce childhood mortality and morbidity in the developing world, reduce the risk 
of massive measles outbreaks and in hopes of fully eradicating the measles virus, new and 
efficacious advances in measles vaccination need to be developed and implemented. 
The first reported experimental measles vaccination was performed in 1758 by 
Scottish Doctor Francis Home, who gathered blood from measles patients “when it contained 
the morbilic matter in the highest state of acrimony”, or at the peak of fever, when the 
patient’s natural defenses were working hardest against the virus (Rebits, Bennett et al. 
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2007).  Delivery of this blood, or nasal discharges from measles patients, to uninfected 
children reportedly proved to provide protection from measles infection.  Unfortunately 
subsequent research did not back up these initial observations and extensive research into the 
development of a measles vaccine was not resumed until the 1950s-1960s.  In 1954, 
researchers Enders and Peebles were the first to isolate a strain of measles, referred to as the 
Edmonston strain, named for David Edmonston, a 13-year old boy from which it was 
collected (Artenstein 2010).  Research into methods of viral attenuation began in the early 
60s and these attenuated viral bodies were incorporated into vaccines which proved to 
provide good immunogenic response (Black 1982).  Viral infectivity was reduced by multiple 
passages through non-human cell lines.  Many different methods of viral attenuation and 
strains of measles have been used for vaccination since the 1960s.  Currently, the most 
extensively used live attenuated measles vaccine strain in developing countries is the 
Edmonston-Zagreb (EZ) strain, which is attenuated by passage in human diploid cells 
(Mathers, Fat et al. 2008).  It is this form of attenuated measles virus, obtained from the 
Serum Institute of India, in Pune, that we have reformulated for dry powder delivery. 
3.1.1 Measles Vaccination 
Literature reviews of measles vaccination field campaigns have shown vaccine 
effectiveness of 77.0% when received at 9-11 months and 92.0% when delivered to children 
≥ 12 months (Enders 1961).  The difference in effectiveness for these age groups is due to the 
presence of varying levels of maternal antibodies in younger children. If the attenuated virus 
is prevented from replicating by existent antibodies, the immune system of the recipient does 
not develop a strong immunity to the infective agent.  This study also showed that the average 
vaccine effectiveness for 2 doses of a vaccine against measles versus no vaccine at all was 
94.1%, showing excellent protection from measles with a 2-dose vaccination campaign.  
Measles vaccine is considered to be the only candidate for successful elimination of measles 
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from defined geographical locations.  In 127 developing countries, the strain of measles 
vaccine provided by the Serum Institute of India is the Edmonston-Zygreb (E.Z strain).  In 
the U.S. and Europe the primary measles vaccine used is the Attenuvax , an additionally 
attenuated strain of the Enders’ attenuated Edmonston strain, produced by Merck, or Priorex 
from GlaxoSmithKline, using the Schwartz attenuated measles strain. 
Extensive field studies show that measles can be essentially eradicated with thorough 
vaccination campaigns.  In the African country of the Gambia, elaborate vaccine campaigns 
in the late 1960s  reached an estimated 96% of children between 6 and 36 months and 
reduced the incidence of reported measles cases from the thousands to the single digits, or 
essentially non-existent (Artenstein 2010).  Vaccinations were delivered using a jet-injection 
gun rather than disposable needles and were maintained with regional vaccination campaigns 
every 12 months, where all children between 6 to 18 months old were vaccinated.  This 
maintained low rates of measles infection, until funding ran out in 1971.  In 1977-1979 an 
average number of 2,036 cases of measles were reported in the Gambia (approximate 
population 400,000) (Black 1982).  If a concerted effort is to be put forward to eradicate this 
disease through vaccination campaigns in wide areas there is a need for future economical, 
effective and safely delivered method of measles vaccination.  Needle-free options are 
expected to include wet mist aerosol and the dry powder aerosol (MVDP) that is the subject 
of this chapter. 
In the early 1960s, shortly after the initial formulation of the measles vaccine (using 
both killed and live-attenuated virus), research was conducted on the immune response to 
vaccine delivered by inhaled aerosol in Japan, the US and the USSR (reviewed in (Artenstein 
2010)).  Results of these tests, which used antiquated testing methods and inefficient liquid 
nebulizers, nonetheless provided evidence that children immunized by the inhalation route 
could demonstrate seroconversion rates comparable to children given the vaccine by 
injection.  Unfortunately, these successful results were not immediately followed by 
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extensive research into measles immunization by inhalation.  The push for additional research 
into aerosol delivery of vaccines was led by Dr. Albert B. Sabin with his research on and 
vaccination campaigns employing nebulized liquid vaccine, conducted in the early 1980s. 
In 1982 and 1983 field studies conducted by A.B. Sabin et al in Mexico and Brazil 
showed that children can be effectively vaccinated for measles with mass vaccination 
campaigns using the aerosol delivery route (Uzicanin and Zimmerman 2011).  In these 
campaigns, vaccination was conducted using lyophilized measles vaccine originally intended 
for injection, rehydrated with sterile water directly before aerosol delivery.  The liquid 
vaccine was stored on ice and nebulized using an industrial air pump and delivered to 
children using inexpensive and simple face masks (modified “Dixie cups”).  Dr. Sabin 
estimated in 1991 that, using a foot powered nebulizer pump and reconstituted lyophilized 
measles vaccine, an organized campaign following Sabin’s procedures could successfully 
vaccinate over 10 million children by wet mist in one day for a cost of $300,000.  This was 
1/6
th
 of the cost of a similarly sized 30 day vaccination campaign using disposable needles 
(Sabin 1991).  Interestingly, Sabin’s hypothesis is mirrored by a recent paper analyzing the 
cost-effectiveness of the most promising innovations in measles vaccination (Sabin 1991).  
The results of the study show that, despite the large cost of initial research and development, 
aggregate cost savings over the next 40 years could be as large as $154.1 million for a 
nebulized aerosol vaccine and $689.4 million for the inhalable dry powder measles vaccine, 
being studied here. 
3.2 Design of a Dry Powder Measles Vaccine 
 
Our work, under the FNIH Grand Challenges in World Health Initiative, has 
concentrated on the formulation, analysis and testing of a dry powder live-virus measles 
vaccine for pulmonary delivery.  Using the Edmonston-Zagreb attenuated virus vaccine 
provided by the Serum Institute of India (Pune, India) a dry powder vaccine, with particles in 
  
39 
 
the inhalable range (1-5 µm DA) for delivery to the lung  has been formulated and processed 
by CAN-BD (Sabin 1983).    The primary change made to the powder formulation, as 
compared to its initial lyophilized form, was the replacement of the sugar sorbitol (at a level 
of about 50%(m/m) in the final powder) with an equivalent percentage of the novel excipient 
myo-inostiol.  This myo-inositol containing formulation demonstrated a significantly 
decreased hygroscopicity and a higher glass transition temperature than the sorbitol-based 
commercial lyophilized cake.  This shows an increase in the stability of the physical 
properties, which is required for an inhaled product, where aerosol behavior is intimately 
related to efficacy.   Further tests of our formulation have shown viral stability exemplified 
by less than 1 log loss of Plaque Forming Units (PFU) under storage conditions of 37 °C for 1 
week, matching the stability of the original lyophilized formulation and meeting the WHO 
requirements of vaccine stability at elevated temperatures.  Continued investigation of our 
formulation has shown less than 1 log loss of activity by PFU after storage at 2-8 °C for 43 
months (Sabin, Decastro et al. 1982; Sabin 1991).  Data obtained by collaborators at the 
Serum Institute of India indicate that the reformulated vaccine has a shelf life of 6 months at a 
storage temperature of 25° C. 
Delivery of our dry powder measles vaccine to cotton rats by inhalation shows 
deposition and replication of measles virus in the lungs, verified by measles-specific reverse 
transcription polymerase chain reaction (RT-PCR) (Sabin 1991).  Measles virus replication 
was confined to the lungs and airways and showed no evidence of transportation to the brain, 
liver, spleen or kidney.  The powder was delivered to cotton rats using the Aktiv-Dry 
PuffHaler, where powder was dispersed into a powder reservoir and rats were allowed to 
breathe at liberty from the suspended powder.  An estimated 0.1% of the powder was 
deposited in the lungs, with some additional deposition of powder in the nasal passages.  
Despite this low dose, a detectable immune response was recorded in response to the viral 
replication. 
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In 2006, a study using a dry powder measles vaccine, formulated by a different 
research group (Garrison, Bauch et al. 2011), was delivered to a non-human primate model, 
cynomolgus macaques, by direct insufflation into the lungs (Burger, Cape et al. 2008).  While 
this study showed poor immunogenicity, delivery of our dry powder measles vaccine 
formulation directly to the lungs by at liberty breathing has shown very positive 
immunogenic results in non-human primates (Stephen P Cape 2011).  Vaccine powder was 
delivered to rhesus macaques using two different active dry powder inhalers (PuffHaler and 
the BD Solovent) and direct intranasal dispersion of the powder using the dispersing units of 
the PuffHaler and Solovent.  No adverse effects were noted in the vaccinated animals.  All 
animals showed evidence of viral replication in the cells of the respiratory system and strong 
anti-measles humoral and cellular immune responses.  When challenged with wild-type 
measles virus 14-16 months after vaccination, all the animals vaccinated by dry powder 
measles vaccine with a passive dry powder inhaler through a face mask showed complete 
protection (Kisich, Higgins et al. 2011).  These tests validate the efficacy of our dry powder 
measles vaccine formulation and delivery method and help  justify progression of the vaccine 
to Phase I safety trials in humans. 
3.3 Characterization of Dry Powder Measles Vaccine 
During the development of our dry powder measles vaccine (MVDP) many tests 
were conducted to ensure uniform powder and vaccine quality.  Powder was analyzed by ACI 
for particle sizes, Karl Fischer titration for moisture content and differential scanning 
calorimetry for thermal properties (glass transition (Tg) and melting point).  Powder was 
analyzed for crystallinity by powder X-ray Diffraction (XRD) and for identity by NMR.   
All placebo (not containing live-attenuated virus) MVDP powder analyzed showed evidence 
of being amorphous by pXRD.  Powder X-ray Diffractograms, obtained by the procedure 
outlined in the Methods chapter, showed an “amorphous  hump” associated with amorphous 
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character rather than discrete peaks which would be produced by a significant amount of 
repeating crystalline cells, Figure 3.1.  
 
Figure 3.1 pXRD Diffractogram of MVDP placebo powder 
Figure 3.1 also shows the pXRD Diffraction pattern for a sample of the placebo 
exposed to a relative humidity of 50 %.  Some sugars are known to transition from a glassy 
matrix to a crystalline form after exposure to environmental moisture (LiCalsi, Maniaci et al. 
2001). It can be seen that no distinct peaks arose in the material exposed to a high humidity.  
Any apparent differences from the dry placebo are likely due to slight variances in the 
analysis, such as the sample backing, or due to sample presentation; the moist placebo was in 
a sticky paste as compared to the fine powder of the dry material.   
Due to the limited sensitivity of the pXRD, we cannot discard the possibility of a 
microcrystalline structure of components of powder.  Many of the excipients included in the 
MVDP formulation will form a crystalline powder when processed by CAN-BD alone or at 
high concentrations.  In combination with the other excipients, such as the plasticizer, gelatin, 
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it is thought that the combined formulation will not contain a high enough local concentration 
to facilitate extensive crystallization.  This produces a powder made of an amorphous sugar 
glass with an observed Tg of about 60 °C (de Swart, LiCalsi et al. 2007).  An amorphous 
formulation was desired to enhance the stability of the measles virus particles, as crystalline 
structures are known to have a unyielding character that may lead to the puncture of the viral 
membrane or the denaturing of the viral proteins (Lin, Griffin et al. 2011).   
3.3.1 NMR Analysis of Measles Vaccine Placebo 
The raw vaccine material we used in powder processing was prepared in India by our 
collaborators, the Serum Institute of India (Pune, India), and shipped to the US as a frozen 
liquid.  It was very important to note any differences in the quality and physical properties of 
this vaccine to ensure the production of a uniform dry powder vaccine.  One particular batch 
of liquid stock material of MVDP sent from India was noted as being less viscous than 
previous batches of vaccine material.  Analysis of total dissolved solids showed a slight 
decrease in the solids content of the material.  NMR identification studies were conducted to 
determine the cause of the compositional differences between the two liquid powder batches 
with differing viscosities. 
In order to analyze the apparent differences between the original and less viscous 
placebo three samples were prepared for NMR analysis.  Samples of the less viscous liquid 
placebo and the original liquid placebo were diluted 1:1 with D2O, in order to reduce the O-H 
interference in the NMR spectra due to water.  A sample of powder prepared from the new 
placebo was reconstituted to a concentration of 10% total dissolved solids with a 1:1 solution 
of water and D2O, in order to be comparable to the liquid placebo.  These samples were 
analyzed to obtain their H
1
 NMR spectra by the Varian Inova 500 NMR instrument at the CU 
NMR facility as described in the Methods chapter.  WET water suppression was used in each 
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run and the final NMR spectra were analyzed by MestReNova NMR spectra-processing 
software.    
 The NMR spectrum of each sample appeared to have the same constituents, based on 
brief inspection of the spectra, Figures 3.2.1 and 3.2.2.  All of the spectra show the 
characteristic myo-inositol triplet at 4.02 ppm (Lin, Griffin et al. 2011) and all have analogous 
peaks for the other components. The proton NMR peaks were assigned to different hydrogen 
environments based on NMR shift tables (Schebor, Mazzobre et al. 2010).  The peaks at 7.8 
and 7.05 ppm are likely due to an aromatic proton (Ar-H), most likely of histidine.  The peak 
at 0.9 ppm is likely R-CH3, 1.45 ppm is R2-CH2, 1.65 ppm is R3-CH and 1.85 ppm is C=C-
CH3.  These peaks are not present in the NMR spectra of stock myo-inositol and are thus 
associated with the other components (amino acids, gelatin, trace sugars, etc.).  The peak 
associated with myo-inositol is at the triplet at 4.02 ppm and is representative of H-C-OH.   
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Figure 3.2.1 NMR of measles vaccine placebo 
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Figure 3.3.1 NMR of different placebos, zoomed into myo-inositol region 
 
 
 
In order to compare the molecular ratios of the different components, the myo-
inositol triplet at 4.02 ppm was set as the reference by setting its integrated area to 1.0.  
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Molecular ratios in a complex mixture were be determined by the relative ratios of the 
integrated areas of the peaks.  For comparison the peaks at 7.05, 7.82, 1.9, 1.65, 1.45 and 0.9 
ppm were chosen. The peaks at these values were integrated and the resulting areas were 
compared between the less viscous placebo liquid, placebo powder made from this liquid and 
the original placebo liquid spectra (Table 3.1).  
Table 3.1 NMR relative integration studies 
 
From Table 3.1 it can be seen that the molecular ratios between the less viscous 
placebo liquid and powder samples are nearly identical, but when compared to the original 
liquid placebo, the molecular ratios are consistently lower.  This implies that the ratios of 
myo-inositol to the other components of the placebo mixture are the same before and after 
CAN-BD processing, but are different between the new and old placebo formulation.  
Furthermore, the changes in ratios are not consistent, as would be expected if the 
concentration of only one component were altered, but each component has an altered 
molecular ratio, implying a change in the relative concentration of at least 2 different 
components.   From this data it was concluded that the concentrations of the components in 
the less viscous and original placebo formulation are not the same, as has been implied by the 
total dissolved solids and viscosity observations.  The difference between the original and 
less viscous formulations was not only related to the ratio of only one component, several 
myo ref 4ppm =1.0             
Associated protons  C=C-CH3  R3-CH R2-CH2 R-CH3  Ar-H Ar-H 
NMR 1.9 ppm 1.65ppm 1.45ppm 0.9ppm 7.05ppm 7.82ppm 
Less viscous powder 0.73 0.82 0.17 0.31 0.06 0.06 
Less viscous liquid 0.74 0.8 0.17 0.32 0.06 0.06 
average 0.735 0.81 0.17 0.315 0.06 0.06 
Original placebo liquid 0.63 0.69 0.13 0.24 0.04 0.04 
% difference 14.3 14.8 23.5 23.8 33.3 33.3 
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concentrations had been altered. This was postulated to have arisen because the aqueous 
solubilities of some of the constituents were exceeded at lower temperatures or high 
concentrations.  The resulting physical separation by crystallization or removal by filtration 
would result in an altered constituent ratio.  Adjustments were made to the formulation 
preparation by lower solids concentrations, and a new placebo formulation, more consistent 
and representative of the original formulation was obtained and used for subsequent powder 
production and tests. 
3.4 Dry Powder Vaccine Activity Homogeneity 
In the production of a dry powder measles vaccine, it was desired to demonstrate the 
homogeneity of the viral particles in the powder has been called to question.  Ideally, 
vaccination is achieved by delivering particles below 5 µm in aerodynamic diameter to the 
deep lung and alveoli where the dry powder is quickly dissolved in the thin aqueous layer on 
the lung epithelium. Viral particles are exposed to the immune system through dendritic cells, 
macrophage scavenging or goblet cells.  In order to verify this route of immunization our 
group sought to prove that the viral particles were in particles of our active formation at 
sufficient concentration, irrespective of particle size.    
 Fine droplet formation in an atomizing spray is an essential element of  rapid drying 
and fine particle formation.   As the high pressure emulsion of near critical CO2 and liquid 
solution exits the restrictor opening, it forms a fine spray of liquid droplets with some 
dissolved CO2 ,  which quickly vaporizes, further nebulizing the liquid of interest.  This is 
very difficult to characterize due to the fast kinetics, microscopic scale and large 
concentration of liquid droplets.  Doubtless, in the highly concentrated spray, there are many 
concurrent droplet-droplet interactions that are very difficult to model.  As the micro- and 
nano-scale droplets are exposed to the drying gas, water vapor leaving the droplet cools the 
remainder of the droplet by evaporation until the droplet is essentially fully dry, at which 
point it can come into equilibrium with the drying gas.  In this case smaller particles, and the 
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active ingredients (viral particles) in them, may lose water faster and  be exposed to higher 
temperatures than in the larger particles which take longer to dry.  Some have worried that 
this could lead to greater thermal degradation in the smaller particles.  Smaller particles will 
also have larger surface areas leading to a decreased potential of full surface coverage of the 
active ingredient (viral particle) with sufficient excipient, which could lead to increased 
degradation.  The following experiments demonstrate that there was no detectible difference 
in the viral activity per unit mass for the particle size ranges observed by ACI. 
 In nature, some species of bacteria have been known to aid in ice nucleation (Maki 
1974) by lowering the freezing temperature of water and have been used to seed clouds.  This 
trait was evolved by this bacteria to produce ice crystals in the cells of plant leaves, aiding 
access of the bacteria to the nutrients inside.  While the EZ measles vaccine is not likely to 
have evolved this unique ability, the surface proteins and viral membrane may act to 
influence nucleation or hydration during the particle forming process.  Additionally, the large 
Peclet number of a 300 nm viral particle may result in a higher surface to bulk ratio of the 
viral concentration.  This could lead to an increased opportunity of degradation on surfaces of 
smaller particles where the surface area to volume is larger than that of larger particles 
(Burger, Cape et al. 2008) 
 Collection, storage and further processing, such as filling into delivery devices, may 
also disproportionately affect particles.  Particle size differences can lead to differences in 
electrostatic charging, thermal resistance and sheer forces which may affect the viability of 
the viral particles contained within the primary particle.  Smaller particles have a larger 
tendency to aggregate and may form larger aggregate particles that will not be differentiated 
from larger primary particles. 
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3.4.1 Activity ACI, Experimental Design 
In order to determine the homogeneity of the active measles virus particles within our 
dry powder we designed an experiment to measure the activity of particles segregated by size 
range.  Particles can be separated by aerodynamic diameter in a non-destructive manner by 
inertial separation with Andersen Cascade Impaction (ACI).  ACI separates particles into size 
bins on plates beneath certified stages.  Size separation is achieved because the flow rates 
increase progressively through the stages by sequentially reducing the total area of the pores 
inset into the stages.  This causes particles with higher momentum than the calculated cut-off 
to impact on the plate of the stage.  For our studies, a modified 5-stage ACI was used to 
collect the particles in different bins representing a range of size fractions.   
 A Westech stainless steel ACI was used for all testing.  Stages 0,1,3,5 and F were 
used with an aluminum neck for coarse particle removal, the aerodynamic diameter cutoff 
(run at 28.8 L/min) for each stage is shown in Table 3.2 
Stage D 50 Cutoff (µm) in aerodynamic diameter 
0 8.7 
1 6.4 
3 2.7 
5 0.94 
F 0.44 mm glass fiber filter 
Table 3.2 Diameter cutoff for each stage used in the Andersen Cascade Impactor. 
As reported above, particles between 0.94 µm and 2.7 µm were collected on stage 5, 
and so on, with particles 8.7 µm and above impacting on stage 0 and all particles below 0.94 
µm collected on the glass fiber filter at stage F.  Preliminary tests used sterilized Nylon filters 
placed on stages 3, 5 and F, but there was significant difficulty with filter seating and airflow 
resistance on stage F.  In the reported studies, powder was collected on ungreased stainless 
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steel plates.  Testing using vaccine placebo and greased plates showed no statistical 
difference from the ungreased results and the added difficulty of inaccurate gravimetric 
measurement, possible incomplete dissolution, and cell culture interference was avoided.   
Plates, stages and tools were cleaned and autoclaved, all experiments were conducted in an 
antiseptic environment inside a BSL II cabinet.  Any testing supply that was not amenable to 
autoclaving was sanitized with 70 % isopropyl alcohol and ultraviolet radiation.  Three 
PuffHaler blisters of live virus measles vaccine powder (Batch no. 68 produced at Serum 
Institute of India (SII)) and Plates 0,1,3,5 and a glass fiber filter were weighed before testing 
and placed in PuffHaler Dispersers.  With a flow rate of 28.8 L/min through the ACI, three 
separate actuations were made into the same PuffHaler spacer and mask using a standard 
bulb.  The spacer mask was placed over the ACI inlet and emptied before the next actuation.  
In all tests the same operator squeezed the bulb, for consistent actuation.  Empty blisters, 
plates and the glass fiber filter were weighed with powder, plates were transferred to sterile 
Petri dishes.  Each plate was washed with 3 ml of sterile PBS solution and all powder was 
dissolved by visual inspection, this sample was transferred to a sterile vial for viral activity 
assay.  The final filter was not tested for activity due to difficulties with incomplete 
dissolution of the powder, loss of liquid to the filter and potential of loss of viral particles to 
the filter material.  Washed and dried PuffHaler blisters were weighed to elucidate the initial 
fill weight of the blister.   
3.4.2 Results of Activity Homogeneity Study 
Viral assay testing of the material collected from each of the stages was conducted in Dr. 
Mark Hernandez’s lab by Dr. Meg Howard.  Viral content was reported in log 50% Cell 
Culture Infective Dose (CCID50) per mg as determined in Vero Cells.  The particle size range, 
determined by the cutoff diameters of each stage used, was organized into size bins and 
shows a distribution with a median size of 3.3 to 5.8 m DA , shown in Figure 3.2. 
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Figure 3.2 Particle size range of MVDP powder as analyzed by ACI 
The viral activity was scaled with the mass of particles deposited on each stage and 
can be seen plotted in Figure 3.3 . 
 
Figure 3.3 Viral activity (Log CCID50/mg powder ) vs. vaccine powder particle size. 
 
  
52 
 
From this experiment it can be seen that the distribution of infective viral particles is 
homogeneous among the particles sizes observed.  This implies no particle size effects due to 
the presence or concentration of viral particles. It also shows that there is no apparent 
preferential degradation of infectivity among the particle sizes observed.  This shows that our 
dry powder measles vaccine can be effective in delivering live-attenuated measles virus 
throughout the pulmonary system, based on particle size-specific deposition.  This particle 
size spread may result in more thorough deposition of the live-attenuated virus through the 
mucosal surfaces of the entire respiratory tract, simulating a wild-type infection and 
improving natural immune response. 
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________________ 
Chapter IV Characterization of myo-Inositol 
________________ 
4.1 Properties of Excipients 
Except in very rare situations, pharmaceutical preparations are formulated with 
excipients to control the physical properties and increase product stability.  Excipients are the 
inactive compounds included in pharmaceutical preparations to serve as bulking agents, or to 
stabilize the physical properties of the product or the activity of the pharmaceutical.  The 
thorough characterization of potential excipients is very important in pharmaceutical 
chemistry and for regulatory purposes.   Different properties of pharmaceutical excipients 
have a large influence on the utility and processing conditions that can be employed.  
Commonly used excipient compounds are amino acids, peptides (such as partially hydrolyzed 
gelatin), polymers, buffers and sugars.   
For materials in which the activity of the ingredient is reliant on a particular shape 
and folding of a macromolecule, such as a protein or live virus, potential excipients can be 
defined as chaotropes or kosmotropes, based on their interactions with the water in solution 
and around dissolved macromolecules.  Chaotropes and kosmotropes were originally 
described by the Hoffmeister series in 1888, a scale of common solute ions arranged in order 
of their experimentally determined  ability to decrease or increase the solubility of protein 
(Crowe, Carpenter et al. 1998).  Kosmotropes (e.g., carbonate anions and sulfate anions) are 
known to decrease protein solubility, “salting out”, and may increase protein stability.   
Chaotropes (e.g., thiocyanate and chromate) enhance protein solubility but can decrease 
protein stability (and create toxicity concerns) (Abraham, Byrne et al. 2005).  The 
Hoffmeister effect is dependent on solute concentration and is a result of direct interaction of 
the solutes with the water molecules arranged at the interfacial surface of the macromolecule 
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(Nord, Vaag et al. 2004).  A well-ordered hydration shell around a dissolved protein will lead 
to decreased structural denaturation during the drying process.    
Some nonionic compounds, particularly those with an abundance of polar side 
groups, are observed to have a similar effect.  This is due primarily to the strong interactions 
of polar bonds with the interfacial waters of hydration around the macromolecules.  This 
effect is noted with disaccharides, maltose and trehalose, (Vehring 2008) and polyols 
(Vehring 2008).   
Crystal formation in excipients may result in the formation of a number of different 
crystal polymorphs or a combination of several of these polymorphs.  Crystal polymorphs, 
here defined as materials that differ in apparent crystal structure while retaining the same 
molecular identity, can have very different properties, such as solubility, instability, and 
biological activity, which can affect the final product.  These crystal polymorphs can result 
from different processing parameters or storage conditions. Lactose, for instance, has four 
well-known crystal forms (Zhang and Cremer 2006) resulting from different crystallization 
techniques or natural chemical isomerizations.  Each of these crystal forms shows different 
chemical properties, some of which may not be desirable in the final product.   
In order to stabilize proteins and sensitive bioactive molecules, crystalline excipients 
are generally avoided, when possible.  The formation of crystalline surfaces by freezing 
solvents or crystallization of excipients can denature proteins or lyse cell membranes at the 
crystal interface (Zhang and Cremer 2006).  In the formulation of lyophilized and other dried 
products, cryoprotectants that prevent crystal formation are included to retain activity of the 
product during processing and storage.  Some cryoprotectants and other added excipients can 
add additional product stability by encasing the active ingredient in a glassy matrix (Marcus 
2010).  Certain sugars are especially applicable to protein or live virus based formulations in 
that they can form sugar glasses, or amorphous matrices, under specific processing 
conditions.  
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 Sugar glasses are a low viscosity state of matter, consisting of random arrangements 
of sugar molecules; they have a viscosity above that of the liquid phase yet below that of the 
solid, crystalline phase.  In dried formulations with proteins or other hydrophilic molecules, it 
is believed that the randomly arranged hydroxyl groups of the sugar replace water molecules 
lost in the drying phase (Magazu, Migliardo et al. 2005).  This stabilizes the hydrophilic 
molecule in its native form, which is important for the bioactivity or immunogenicity of that 
active ingredient.  This phenomena is noted in nature in the high concentration of trehalose (a 
disacchride prone to glass formation) in the cells of  certain mushrooms and the desiccated 
embryos of brine shrimp (“sea monkeys”) which can survive periods of dehydration and 
revive upon the addition of water (Uedaira 2001).  Lyophilized or spray dried formulations 
have been stabilized by the formation of glasses of sugars such as trehalose, sorbitol, sucrose 
and myo-inositol. 
 The stability of these sugar glasses is dependent on the temperature of storage, 
additional additives and humidity of the material.  At temperatures 10 to 30 °C above the 
glass transition temperature (Tg, a characteristic temperature of an amorphous material 
indicated by a slight thermal transition and a viscosity change (Kirk, Dann et al. 2007), the 
viscosity of the glass decreases, resulting in a phase of material known as the rubbery state 
(Chang, Kendrick et al. 1996).  The rubbery state can allow the flow of the sugar matrix, 
leading changes of the physical shape of the material and fusion to neighboring particles and 
surfaces.  Potential matrix-forming excipients can be categorized as: eutectic, glass-forming 
or doubly-unstable. 
Eutectic materials, such as NaCl, have a lower eutectic point (Te), or temperature of 
crystallization, compared to their glass transition point.  These materials, in the absence of 
sufficient interference, will tend to crystallize before they form a glass (Imamura, Ogawa et 
al. 2003), and are undesirable as stabilizing agents.   Glass-forming materials exist as glasses 
when sufficiently concentrated and exhibit a glass transition significantly below their 
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crystallization temperature.   The sugars, trehalose and sorbitol, are commonly cited as good 
glass-forming excipients, as they can readily form glasses with Tg of 120 °C and 77 °C, 
respectively, and resist crystallization during brief exposures to temperatures above their Tg 
(Crowe, Carpenter et al. 1998).  Doubly-unstable excipients can form glasses on 
concentration but may crystallize during processing or storage.   Recrystallization can be 
related to the difference between material temperature and its Tg and time, meaning that 
extended periods of exposure to temperatures moderately above the Tg can carry the same 
crystallization potential as brief excursions to temperatures well above the Tg (Hengherr, 
Schill et al. 2011).   Mannitol is a sugar alcohol classified as doubly unstable, yet it is 
currently investigated as a lyoprotectant or stabilizer for freeze dried and spray dried  
formulations (Simperler, Kornherr et al. 2006).  Mannitol can only be used as a lyoprotectant 
in its amorphous form, so it is formulated with additional excipients; amino acids, salts and 
other sugars, to impede crystallization (Turchiuli, Gianfrancesco et al. 2011). 
 The addition of other excipients, for example; ions, amino acids and some proteins, 
can improve the amorphous properties of materials by inhibiting crystal formation (Gearing, 
Malik et al. 2010).  These materials must be carefully dosed into the final formulation as they 
can also act as plasticizing agents, lowering the overall glass transition temperature of the 
formulation.  One of the strongest and most ubiquitous plasticizing agents is water, which can 
greatly increase the Tg of a formulation in small concentrations (Hatley and Blair 1999), so 
hygroscopicity, or ability to take up atmospheric water, should be avoided if possible.  
Amorphous materials are generally more hygroscopic than their crystalline counterparts, as 
water molecules are more mobile within and through a disorganized glass than a well-ordered 
crystal (Hatley and Blair 1999).  In order to avoid water uptake, dried products are typically 
handled in dry box environments, purged to a low humidity (<20% RH) with dry gas.  Dried 
products should be stored in sealed impermeable containers and moisture impermeable 
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secondary containment (such as foil overwrap) with sufficient desiccant, to remove and 
maintain at low levels any residual atmospheric moisture. 
During our research into the formulation of a dry powder measles vaccine for 
inhalation, many different sugar excipients were investigated (Sadrzadeh, Miller et al. 2010).  
Mannitol, lactose, sucrose, sorbitol, trehalose and myo-inositol were all studied as potential 
sugar excipients.  Mannitol formulations showed a tendency to crystallize after collection on 
the filter.  Lactose, sucrose and sorbitol formulations showed undesirable hygroscopicity in 
the final product.  Powders were formed that fit the desired specifications using both 
trehalose and myo-inositol, but ultimately, a myo-inositol based formulation was chosen, 
because the trehalose formulation showed lower relative viral stability under accelerated 
storage conditions, 7 days at 37 °C (Telang, Yu et al. 2003).  Due to its ability to increase 
viral stability and maintain relatively low hygroscopicity, myo-inositol was thoroughly 
investigated as a potential excipient sugar for dry powder formulations.   
4.2 myo-Inositol 
Inositols (C6H6O12 , M.W. 180.16 amu) are sugar alcohol isomers of glucose that are 
classified as cyclitols; they consist of a 6-carbon ring with one hydroxyl group and one 
hydrogen bound to each carbon.  Inositol has seven distinct optically inactive meso-forms 
(scyllo-, neo-, epi-, muco-, l-chiro,-myo- and allo-) and one optical isomer form (d-chiro-), as 
determined by the axial and equatorial positioning of the hydroxyl groups located around the 
carbon ring (Jayasundera, Adhikari et al. 2011).  Of these possible isomers, myo-inositol is 
the most common in nature.  myo-Inositol (cis-1,2,3,5-trans-4,6-Cyclohexanehexol) is 
arranged with 1 axial and 5 equatorial hydroxyl groups, as shown in Figure 4.1. 
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Figure 4.1 Structure of myo-Insoitol   
 
4.2.1 Identity and sources of myo-Inositol 
Ubiquitous in nature, myo-inositol can be consumed from many natural sources but is 
most concentrated in grains, nuts and fruits such as melons and citrus fruits.  myo-Inositol is a 
vital nutrient in plant metabolism and factors into many chemical pathways related to plant 
growth (Haque and Roos 2004). Found at levels of 4-9 mg/L in normal human plasma (Naini, 
Byron et al. 1998), myo-inositol is consumed by well-nourished individuals at a natural rate 
of about 1 g/day and is notably a major component in human breast milk (Burger, Cape et al. 
2008). This has led to its use as a an additive to infant formulas. myo-Inositol can also be 
produced through enzymatic processing of glucose phosphates in a number of human organs 
and tissues (Burger, Cape et al. 2008). 
   myo-Inositol is listed as generally recognized as safe (GRAS) by the FDA 
and is approved for as a food additive, nutritional supplement and for use in special dietary 
foods (Simperler, Kornherr et al. 2006).  Tolerance of myo-inositol by oral ingestion has been 
found to be up to 18 g/day for 3 months (Loewus and Murthy 2000).  This study was 
conducted to assess the potential of myo-inositol as a chemopreventative agent in smokers 
with bronchial dysplasia.  A significant improvement in the rate of regression of preexisting 
dysplastic lesions was noted in patients receiving oral myo-inositol vs. the placebo group 
(91% to 48%).  An additional interesting and potentially valuable side effect observed in the 
patients receiving myo-inositol at the 18 g/day level was a reduction in the systolic and 
diastolic blood pressure by an average of 10 mm Hg (Kusmierz, Degeorge et al. 1989). 
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4.2.2 Biological Activity of myo-Inositol 
myo-Inositol has been noted to play a significant role in the female reproductive 
system, specifically in that it has been observed to affect fertility, oogenesis, and has been 
shown to have a therapeutic effect when given orally to women who suffer from polycystic 
ovary syndrome (PCOS) (Hallman, Bry et al. 1992).  While there are yet to be universally 
agreed upon diagnostic symptoms of PCOS, it is thought to be the most common 
endocrinopathy observed in women (Pereira, Baker et al. 1990).  Symptoms may include 
hyperandrogenism, polycystic-appearing ovaries, obesity, irregular ovulation and 
irregularities in estrogen and insulin regulation.  Studies have found that regular oral doses of 
inositol can result in decreased blood-pressure, lowered blood triglycerides, improved insulin 
regulation, reduction of hirsuitism, and improved ovulation regularity in women diagnosed 
with PCOS (FDA 2011). 
myo-Inositol is a relatively strong and mobile osmolyte, a compound which regulates 
osmosis and water transport, which are known stabilizers of membranes and proteins (Lam, 
McWilliams et al. 2006).  The potential for a material to stabilize a protein can be 
approximated by its dynamic hydration number (DHN), a physical quantity related to the 
enthalpy of hydration of a solute.  When compared with similar polyols, the presence of myo-
inositol, in solution with several model proteins, has been found to result in a consistently 
larger increase in the temperature of protein degradation.  This may be due to the DHN value 
of 18.6 for myo-inositol as compared to the DHN values of 16.9, 16.2 and 9.9 for sorbitol, 
mannitol and glycerol respectively (Lam, McWilliams et al. 2006).   
4.2.3 Sources of myo-Inositol 
myo-Inositol is commercially derived from grains and by-products, such as rice hulls, 
in the form of phytic acid and phytin (inositol hexaphosphoric acid and its calcium-
magnesium salt), which is found in rice bran at levels as high as 57 mg/g  (Lam, McWilliams 
et al. 2006).  Phytic acid and phytin are commercially separated from the rice bran and are 
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then hydrolyzed, usually by phytase enzymes which remove the six phosphate groups bound 
to the carbons of the inositol ring (Papaleo, Unfer et al. 2009). 
The primary supplier of myo-inositol for this research was Tsuno Rice Fine 
Chemicals Co. Ltd., located in Wakayama, Japan.   The myo-inositol provided by Tsuno was 
a coarse white crystalline powder, with a larger primary particle size than the material 
commercially available from Sigma-Aldrich.  The Tsuno stock material was analyzed by 
powder XRD (Figure 4.2) and NMR, and found to be pure myo-inositol by these methods by 
comparison with literature values (Table 4.1). 
 
Figure 4.1 pXRD of Tsuno Stock myo-Inositol 
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sources were found to be chemically identical by pXRD. The bulk myo-inositol used in our 
testing was purchased in a 25 kg lot and was stored throughout the 5 years of this study 
without detectable change in a large, plastic-lined, sealed fiber drum with exposure to the lab 
atmosphere only during the transfer of 1 kg amounts to a satellite container for lab use.   
4.3 myo-Inositol Toxicity Study 
 In the formulation of a dry powder measles vaccine for delivery by inhalation 
the primary stabilizing excipient used was myo-inositol as 50% of the dry weight of the final 
formulation (Burger 2008).   Powders, processed by CAN-BD, showed superior activity 
retention of the myo-inositol based vaccine powder as compared other formulations using 
different sugar excipients.  The myo-inositol based formulations also show lower moisture 
content under the same processing parameters.  While myo-inositol is a promising excipient, 
biologically ubiquitous and tolerated at high doses by oral delivery, thorough testing of the 
toxicology by inhalation had not been conducted at the outset of this study.  As our dry 
powder measles vaccine was intended for human and test animal inhalation, toxicology 
studies of the inhaled excipient were required to progress to more advanced in vivo trials of 
our product. In November, 2011, approval was given by the Drugs Controller General of 
India to the Serum Institute of India, Ltd., our collaborators in the Grand Challenges in 
Global Health Initiative, to begin the Phase I clinical trials in human volunteers in Pune, India 
of dry powder measles vaccine aerosols stabilized by myo-inositol. This has followed review 
of extensive testing of myo-inositol-containing samples (formulated at the University of 
Colorado) in rats and macaques by collaborators in our team.  An inhalable myo-inositol 
powder was designed to elucidate the toxicity, if any, of inhaled myo-inositol.   
In powder preparation it became immediately apparent that myo-inositol could be 
qualified as a doubly-unstable compound.  Powders of pure myo-inositol produced by the 
CAN-BD process were invariably crystalline and proved to be poor models for inhalable 
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powders, because, from the dry powder inhalers employed, the % mass delivered below 5.8 
m DA was uniformly low.  In order to produce a more efficacious and finer inhalable 
powder, various changes were made in the processing parameters: outlet temperature, drying 
gas flow rate, feed flow rate and feed concentration (Table 4.1) 
Process Parameter feed concentration feed concentration 2 feed concentration 3 
  5% (m/v) 10% (m/v) 1% (m/v) 
Liquid Flow Rate  %< 5.8 m %< 5.8 m %< 5.8 m 
0.3 mL/min 6.46 5.73 3.92 
0.5 mL/min 7.07 8.38 n/a 
Outlet Temp       
50 °C 9.80 7.59  n/a 
70 °C 5.21 6.79 3.92 
Drying Gas        
30 L/min 5.66 8.15  n/a 
40 L/min 5.21 5.10 3.92 
Table 4.1 Average % particles by mass < 5.8 m DA for pure myo-inositol under 
different CAN-BD processing parameters 
In these pilot experiments with pure myo-inositol, no one parameter or combination 
of several was found that produced  a powder with sufficiently small particle size (at least 
35% particles by mass< 5.8 m DA) to prepare a powder representative of our measles 
formulation, which is stabilized with 50 g/L of myo-inositol in the aqueous vaccine feed 
stream for CAN-BD drying and micronization..   
An additional excipient was required to produce a suitable powder, but in order to 
remain representative of the initial formulation we chose potential additive excipients from 
those already present in the dry powder measles vaccine formulation, reported in Table 4.2.  
Additionally, this formulation was known to form an amorphous matrix, when dried by CAN-
BD .  
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Component 
Liquid 
concentration mass % total solids 
  g/L % 
myo-inositol 50 46 
Gelatin (hydrolyzed) 25 23 
L-arginine-HCl 16 15 
L-histidine 2 2 
L-alanine 1 1 
Lactalbumin hydrolysate 4 3 
Tricine 3 3 
Table 4.2 Concentration of formulation components in dry powder measles vaccine 
(MVDP3) 
Powder made using similar amounts of L-arginine and L-histidine only resulted in 
the immediate crystallization of the powder on the surface of the filter, blocking the filter 
pores and stopping the process run.  The same results were noted following the addition of 
mannitol, which is another sugar alcohol used in inhalable powders (Carmina and Lobo 
1999).  The addition of gelatin and lactalbumin was found to produce good powder with a 
FPF of about 35% <5.8 m and 13%<3.4 m.  Lactalbumin at a 1:20 ratio to myo-inositol 
was chosen as a promising additive due to the variability and hygroscopicity of gelatin.   
Lactalbumin, consisting of peptides considerably larger than myo-inositol likely 
resulted in better performing particles as the higher Peclet number of the peptides would 
reduce their mobility, leading to a surface coating of lactalbumin on the microparticles being 
formed.  This would prevent the fusion of the crystalline surface of myo-inositol particles to 
form aggregates (Costantino, Minozzi et al. 2009) as was seen in SEM images of pure myo-
inositol, Figure 4.3.  Long runs for bulk production of the myo-inositol/lactalbumin were 
attempted, but generally resulted in the collection of poorly dispersible flakes from the dual 
filter back pulse system.  A higher flow rate of nitrogen drying gas was used and the chamber 
temperatures were increased from 50 to70 °C, but the problem persisted and the resulting 
flakes were shown to be poorly dispersed.  Long production runs were conducted using a 
different filter system but still resulted in lower than acceptable FPF (28% <5.8 m, 7% 
<3.4m).  SEMs of these powders have all shown small individual particles aggregated to 
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form larger clusters, Figure 4.4.  The problem with these powders appears not to be the 
individual particle size, but particle/particle attractive forces that hold the powder in 
aggregates.  This was probably due to adhesion of the lactalbumin surface coating and was 
seen to be exacerbated at higher humidities. 
 
Figure 4.3 SEM Image of CAN-BD Processed Pure myo-Inositol, fused particles and the 
resulting particle aggregates 
 
 
Figure 4.4 SEM Images of CAN-BD Processed myo-Inositol/Lactalbumin (20:1) and 
powder clusters 
 
  
66 
 
 
 
Figure 4.5 SEM Image of CAN-BD Processed myo-Inositol/l-luecine  (98.5:1.5) 
myo-Inositol powder with respirable fractions sufficiently abundant to serve as a 
representative powder were eventually produced through the addition of l-leucine at a 
1.5%/98.5% ratio with myo-inositol, as seen in Figure 4.5.  Other ratios (i.e. 10%/90%, 
5%/95% and 1%/99%) were tested but the ratio of 1.5%/98.5% was chosen as it produced a 
well-behaved amorphous powder without adding an excess of the additional excipient (l-
leucine).  l-Leucine is a well-known excipient that is frequently used in particle engineering 
to reduce particle aggregation (Auton, Rosgen et al. 2011).  It is thought that the insolubility 
of l-leucine results in the formation of an l-leucine shell around the particle where the 
isobutyl side chain aids in maintaining particle separation.  This is supported by the change in 
the observed surface roughness in particles with increased concentrations of l-leucine.  myo-
Inositol/l-leucine particles shown in Figure 4.6 were prepared at a ratio of 9:1 and 
demonstrate much more irregular surfaces and shapes when compared to myo-inositol/l-
leucine powders at a ratio of 98.5:1.5 in Figure 4.5. 
  
67 
 
 
 
Figure 4.5 SEM Image of CAN-BD Processed myo-Inositol/l-leucine  (9:1) 
A 10 to 15 g batch of inhalable powder, consisting of myo-inositol and l-leucine at a 
98.5/1.5 weight ratio was produced under sterile conditions for inhalation toxicity testing in 
Sprague-Dawley rats.  This powder was tested against a placebo powder prepared from l-
leucine and lactose, a sugar already FDA-approved excipient for inhalation drugs.  
Aerosolized powder was presented to a group of test rats at a dose level up to 30 mg/day for 3 
days by an external contract toxicology testing laboratory.  Powders were aerosolized into a 
powder reservoir and inhaled at-liberty by the test animals.  Emitted dose tests at the typical 
inspiration rate for a rat (0.3 L/min) estimated the dose delivered to rats at a maximum of 10 
mg/Kg.  No adverse effects were noted for any of the dosage groups, indicating that the no-
observed effect level for rats is an exposure of 30 mg/day, while a larger dose may be 
tolerated.  Animal studies were conducted at Bridge Laboratories (now named Avanza in 
Gaithersburg, MD).   These tests provided evidence that myo-inositol can be well tolerated as 
an inhalable excipient and have led to further testing of our myo-inositol-based dry powder 
measles vaccine. 
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4.4 myo-Inositol Crystal Polymorph 
Testing of the myo-inositol formulations of the measles vaccine showed it to be 
amorphous with a glass transition temperature of about 61 ºC, but myo-inositol processed by 
CAN-BD with fewer additional solutes, specifically without gelatin, can form crystalline 
myo-inositol.  It was found that different processing variables could lead to the formation of 
two different crystal polymorphs of pure myo-inositol: the previously studied common form 
of myo-inositol and a metastable polymorph, myo-inositol β.  
The metastable polymorph, as well as the more stable polymorph, was observed at 
CAN-BD drying gas temperatures of 50 °C, while at 60 °C only the more stable polymorph 
was observed to be present.  When the powder containing a mixture of the metastable and 
stable polymorphs was heated to 120 °C, the annealed powder no longer shows the presence 
of the metastable polymorph.  This loss of the metastable polymorph is also noted when the 
mixed powder was stored at room temperature for an extended period of time (several 
months), without any external heating applied after CAN-BD drying at the lower temperature 
was completed.   
Measurement of powder X-ray Diffraction was conducted on the various samples 
according to the methods described in the Methods chapter; scans were run from 2 Theta of 
5° to 45°.  Differential Scanning Calorimetry was conducted as described in the Methods 
chapter, from with analysis from –20 ºC to 250 ºC at scan rates of 10 ºC/min and 100 ºC/min. 
myo-Inositol powder processed by CAN-BD with drying gas below 60 ºC was analyzed by 
powder X ray Diffraction (pXRD) and found to have a significantly different diffraction 
pattern than the diffraction pattern of the unprocessed material, as shown in Figure 7.  The 
most significant reported peaks from the International Center for Diffraction Data database 
(Uedaira 2001) are shown in Table 4.3. 
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Figure 4.7 pXRD Diffractograms for different crystal forms of myo-inositol. 
2 Theta relative intensity 2 Theta relative intensity 
14.7 20 27.9 16 
15.4 30 28.9 45 
17.5 70 31.1 45 
18.8 100 31.5 20 
20.2 90 31.6 20 
23.5 20 34.6 14 
24.0 50 35.1 18 
Table 4.3 Peak values expected for pXRD analysis of myo-inositol  
It can be seen in Figure 4.7 that, in comparison to the stock material, the metastable 
crystal form exhibits three peaks at 2 Theta of 19.1, 19.7 and 22.2 and the major peaks at 2 
Theta of 14.7, 18.8 and 20.2 are absent.  Heating the powder to 145 °C causes the metastable 
crystalline form to revert to the more stable native crystal form.  These diffraction data were 
consistent for all batches of CAN-BD processed pure myo-inositol powder dried below 60 °C 
when measured directly after processing, but over time the metastable crystalline form slowly 
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reverts to the native crystal form, resulting initially in a powder with the X-ray diffraction 
pattern of both crystal forms, Figure 7, and ultimately in only the more stable form. 
 
Figure 4.8 pXRD Diffractogram of aged myo-inositol polymorph powder showing both 
characteristic patterns 
Study of the thermal properties of myo-inositol β powder by differential scanning 
calorimetry (DSC), as seen in Figure 4.9, shows an exothermic transition with an onset at 110 
ºC and a peak at 125 ºC before the melting point at 225 ºC , which is the literature value for 
myo-inositol (Uedaira 2001).  Powder heated above115 ºC no longer exhibits any 
endothermic transition before melting at 225 ºC. 
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Figure 4.9 DSC thermal analysis of myo-inositol β crystalline powder indicating 
recrystallization exotherm 
 The moisture content of the myo-inositol β powder has been determined to be nearly 
the same as the moisture content of myo-inositol powder in the native form (about 0.1%).  A 
very small mass loss was noted after heating the myo-inositol β powder to 145 ºC.  Analysis 
of SEM images of both show no obvious differences. 
  Samples of myo-inositol  powder have been analyzed by a differential vapor 
sorption instrument (DVS) by Surface Measurement Systems Ltd UK.  Samples were held at 
40 ºC and exposed to air flow at controlled steps of relative humidity.  The sample was 
allowed to equilibrate at each step and the percent change in mass from the initial fill weight 
was recorded.  Steps in RH were increased from 0 % to 95 % in 5 % increments and then 
decreased from 95% to 0% in 5% increments.  A small loss of about 0.025% was noted at 
about 19 % relative humidity for each run.  A graphic representation of this analysis can be 
seen in Figure 4.10. Overall, the powder gained 0.2% mass or less over the course of RH 
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increase, with the largest gain being at 95 % RH.  The mass gained during humidification of 
the powder was lost upon the decrease of RH to 0% RH. 
 
Figure 4.10 Differential Vapor Sorption (DVS) study of the meta stable crystalline myo-
inositol 
 Diffraction data taken of earlier-prepared (older) myo-inositol β powders stored and 
room temperature, and of freshly prepared myo-inositol β powders heated to 145 ºC (Figure 
6) show a reversion to the common crystal form. Samples of myo-inositol β powders stored at 
2-8 ºC retain the unique pXRD  diffraction pattern and the exothermic event at 110 ºC for up 
to 5 months. 
 Because myo-inositol is being tested as a new sugar stabilizing excipient, its various 
crystal polymorphs should be characterized and categorized.   A myo-inositol dihydrate has 
been previously reported (Garcia-Estepa, Guerra-Hernandez et al. 1999) but our myo-inositol 
β powders are not the dihydrate from.  The moisture content of the myo-inositol β powders is 
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very low (0.1 % water) and statistically equivalent to the moisture content of the native myo-
inositol.  DSC studies of the myo-inositol β powders show no endothermic dehydration event 
before the material melts at 225 ºC, where the dihydrate is expected to melt at 196 ºC 
(Greiner, Alminger et al. 2002).  Additionally, the powder XRD pattern of the myo-inositol β 
powder does not match that of the published calculated myo-inositol dihydrate pattern 
(Sadrzadeh, Miller et al. 2010). Therefore, it can be reasonably concluded that there are no 
detectable amounts of the dihydrate present in the well-dried myo-inositol stabilized samples 
examined in the present study. 
Samples of myo-inositol β powders that were heated past the exothermic transition at 
120 ºC without melting revert to the native form of myo-inositol, based on X- ray diffraction.  
Heating these samples shows a very low loss in mass that is not statistically different than 
that of native myo-inositol powders, indicating that the difference between these two is solely 
related to the change in crystal structure. 
DVS results for the powder showed a slight decrease in mass (about 0.02%) after 
increasing air RH to 20%.  This is likely due to plasticization of the amorphous content of the 
powder and subsequent crystallization of that portion, resulting in the loss of water adsorbed 
to the previously amorphous content.  Most substances defined as crystalline still have some 
amorphous content, which may go unnoticed by some methods of crystalline content analysis 
(pXRD) (Adhikari, Howes et al. 2009).  Due to its relatively disorganized state, an 
amorphous sugar is usually more susceptible to moisture uptake than a purely crystalline 
form of the same sugar (Vehring 2008).  The addition of water may act to decrease the glass 
transition of the material and can lead to crystallization of the amorphous material (Rudman 
1962), resulting in the loss of water adsorbed to the glassy material.  A large % mass gain 
would be expected for an amorphous form of myo-inositol during exposure to elevated RH 
and so the DVS results imply a low amorphous content of the myo-inositol β powder.    
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The pXRD diffraction pattern of myo-inositol β is not likely due to sample 
preparation artifacts.  Preferred orientation is very unlikely as the particles are in the micron 
and sub-micron range and are randomly arranged.  While there are no reported powder XRD 
diffraction patterns for myo-inositol polymorphs, there are some single crystal diffraction 
patterns of myo-inositol polymorphs (Rudman 1962).  Comparison between our powder X-
ray diffractograms and the single crystal diffraction patterns is very difficult and single-
crystal XRD was not pursued for our material due to the difficulty of separating out one 
particle and the possibility of microcrystalline structure.   
The metastable crystal polymorph noted for CAN-BD processed myo-inositol dried at 
temperatures less than 60 °C may be evidence of a myo-inositol in its energetically 
unfavorable chair formation.  myo-Inositol is known to have two possible chair conformations 
(A and B) seen in Figure 4.11. In crystalline form, calculations based on the theoretical 
coupling constants of each conformation show that chair conformation A is preferred by 30 
kJ/mol over chair B resulting in a theoretical mole ratio of 99:1 (A:B) (Simperler, Watt et al. 
2006). 
 
Figure 4.11Structure of the favored (A) and unfavored (B) chair conformations of myo-
inositol. 
The CAN-BD spray drying process, with lower drying temperatures, may lead to the 
formation of a near pure crystalline powder of the thermodynamically unfavored (but 
kinetically accessible) chair configuration, but further computational analysis will be required 
to prove this.  Models of infinite hydrogen bond chains of myo-inositol show that myo-
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inositol crystals follow an irregular double chain parallel pattern where molecules sharing 
two OH bonds with a neighbor molecule alternate with molecules sharing only one OH bond 
(Bonnet, Jones et al. 2006).  The irregular crystal pattern, in conjunction with an additional 
possible chair conformer may explain the added stabilization properties of myo-inositol, 
where a crystalline matrix can be sufficiently irregular to provide the same benefits as an 
amorphous material.  Still, as exemplified by the metastable character of CAN-BD processed 
myo-inositol, care must be taken to prevent the crystalline rearrangement of myo-inositol in a 
formulation. 
4.5 Differentiation from scyllo-Inositol 
Of the eight different isomers in the inositol family, the second most common 
naturally found stereoisomer of inositol is scyllo-inositol.  Originally derived from the kidney 
of dogfish (genus Scyllium), it is also found naturally in acorns  (Bonnet, Jones et al. 2006).  
scyllo -Inositol has been identified in healthy brain tissues at concentrations of 0.3 mM for 
young subjects and 0.43 mM for older subjects (Terakita, Matsunaga et al. 2009).  Studies 
have shown transgenic mice with Alzheimer’s disease treated with oral scyllo -inositol have 
shown a decrease in neurotoxic Aβ oligomers in the brain, leading to the inhibition of typical 
behavior defects (Ward and Schultz 1995).  In 2009, Elan Corporation, plc and Transition 
Therapeutics, Inc.  were conducting clinical trials of orally delivered scyllo -inositol in human 
Alzheimer’s  patients, and, as of Dec 2009, ended the higher dose patient groups (1000 mg 
and 2000 mg dosed twice daily) due to possible adverse effects (Hancock and Dalton 1999). 
   
Due to speculation, subsequently proven to be groundless,  that myo -inositol previously used 
for powder production might have contained small amounts of scyllo -inositol, high field, 
high resolution NMR analysis was conducted to confirm the purity of stock myo -inositol, in 
respect to the stereoisomer scyllo -inositol.  scyllo -Inositol has a reported melting point of  
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325 ºC (Hancock and Dalton 1999) which is significantly higher than the melting point 
observed for the stock myo -inositol, 225 ºC.  scyllo -Inositol is a carbon symmetric molecule 
with only one singlet by 
1
H NMR at 3.34 ppm (Khan, Qureshi et al. 2007), structure shown in 
Figure 4.12.   
 
Figure 4.12 Structure of scyllo-inositol 
myo -Inositol by contrast has expected peaks at 3.259 ppm, 3.282 ppm, 3.305 ppm, 
3.523 ppm, 3.53 ppm, 3.548 ppm, and 3.555 ppm (SalazarPereda, MartinezMartinez et al. 
1997).  The 
1
H NMR spectra of stock myo -inositol in D2O shows the expected peaks for 
myo-inositol, with no peaks at 3.34 ppm, Figure 4.13.  This shows that no detectable scyllo -
inositol is present in our stock myo -inositol as determined by high field 
1
H NMR.  The 
conversion process for myo-inositol into scyllo-inositol is quite involved (Simperler, Watt et 
al. 2006) and very unlikely to occur during processing or storage of our formulations; 
furthermore, there is no indication of any such conversion. 
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Figure 4.13 1H NMR spectra of stock myo-inositol in D2O (3.20 ppm to 3.52 ppm)  
 
4.6 myo-Inositol Conclusions  
While it appears to be a doubly unstable sugar, only resulting in crystalline material 
when processed on its own, myo-inositol may prove to become a beneficial new excipient.  
Difficulties in particle formation were overcome through the addition of complementary 
excipients and a toxicology study on the prepared powder showed inhaled myo-inositol to be 
well tolerated in rats at exposures of up to 30 mg/Kg per day for 3 days.  A metastable 
crystalline form of myo-inositol was produced in a near pure form, as assayed by pXRD, by 
CAN-BD processing.  This polymorph may prove to consist of an extensive crystal of the 
thermally unstable chair conformer of myo-inositol.  Additionally, characterization 
techniques, using  pXRD, NMR and DSC, were developed to determine the identity and 
purity of myo-inositol in formulations and both possible crystal forms. 
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________________ 
Chapter V  Development of a Dry Powder Human Papillomavirus Recombinant 
Protein Vaccine 
________________ 
5.1 Human Papillomavirus, Current Vaccines 
 
 Human Papillomavirus (HPV) is currently the most prevalent sexually transmitted 
infection in the US.  Approximately 20 million Americans are currently infected and 5.5 
million more become infected each year (Simperler, Watt et al. 2006).  There is evidence that 
at least 75% of sexually active individuals will be infected with at least one serotype of HPV 
over their lifetimes (Witczak 2008).  Over 100 serotypes of HPV have been identified, the 
majority of which carry a low risk of severe symptoms.  Infections may be asymptomatic or 
may cause warts and lesions and can lead to cervical, penile, anal or throat/neck cancer.  
Some studies have found HPV virus in up to 61% of neck and head cancer samples (Kaiser, 
Schuff et al. 2005).  HPV is the primary cause of cervical cancer, the second leading cause of 
cancer deaths in all women.  One recent study shows that cervical cancer in rural India may 
even be twice as common as breast cancer (McLaurin, Kierstead et al. 2006).  In the US, 
10,000 women are diagnosed with, and 4,000 women die of, cervical cancer every year 
(Salloway, Sperling et al. 2011). Worldwide, there are half a million cases of cervical cancer, 
leading to a quarter million deaths every year (Day, van de Streek et al. 2006).  
 In recent years, effective but expensive vaccines for HPV such as Gardasil and 
Cervarix have gained approval in the US and abroad.  Gardasil consists of recombinant, self-
assembled, virus-like particles (VLPs) made up of HPV L1 capsid proteins of the HPV types 
16, 18 (which cause 70% of cervical cancer) and 11 and 6 (which cause 90% of genital 
warts).  Cervarix contains the VLP antigens to only HPV16 and 18.  Gardasil is 
recommended for girls age 11 to 26, although it may be given to girls as young as 9.  The 
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cutoff of approval at 26 years of age was instituted due to the near ubiquity of HPV in 
sexually active women.  Any sexually-active woman over the age of 26 is likely to have been 
exposed to one of the target varieties of HPV and the immunogenic benefit to the recipient is 
considered to be insufficient to justify vaccination of any woman above that age.  Gardasil is 
a prophylactic vaccine and is not considered therapeutic.  Gardasil has recently been 
approved and shown to be effective at protecting males from HPV infection  (Kaiser, Schuff 
et al. 2005).  Vaccination of males may or may not provide direct and significant benefit to 
the male recipient, but should reduce the spread of HPV (as well as protecting the man from 
the rarer incidences of penile, neck, head and anal cancer as well as genital warts).    For 
these reasons, on Oct 25
th
 2011 the Advisory Committee on Immunization Practices released 
a recommendation that all males, in addition to females, aged 11 to 12, be vaccinated for 
HPV (Kaiser, Schuff et al. 2005). 
 The currently approved vaccines are formulated as liquid suspensions, adjuvated with 
amorphous aluminum hydrophosphate sulfate, in the case of Gardasil, and aluminum 
hydroxide and a proprietary lipid adjuvant, in the case of Cervarix (SDBSWeb).  These 
vaccines are packaged as 0.5 ml liquid vaccine in single dose vials and need to be stored 
between 2 and 8 °C;  elevated temperatures may lead to bacterial growth or protein 
degradation and freezing may lead to vaccine deactivation or separation and precipitation of 
the adjuvants.  The vaccines are given in a 3-dose series over 6 months in order to give 
maximum protection (Husson, Odier et al. 1998).  Due to reports on the efficacy and 
necessity of this vaccine, many states are considering instituting mandatory HPV vaccination 
for school girls as young as 11.  Some states urge vaccination but offer an opt-out.  Due to the 
frequency and ease of infection, the effectiveness of these vaccines are at a maximum when 
they are delivered to women before they become sexually active. 
 The VLPs used in the current vaccines are made up of 72 L1-capsid protein 
pentamers which self-assemble to form virus-like spheres, without the L2 capsid protein and 
  
84 
 
viral genome, thus providing no risk of infection (Moscicki 2005).  In order to produce these 
self-assembled VLPs, the L1 proteins are expressed in and purified from insect cells 
(Cervarix) and yeast (Gardasil) and subsequently extracted and purified.  Research by 
Warzecha et al in 2003 shows that HPV L1 proteins can be expressed in transgenic potatoes 
and these proteins have been shown to self-assemble into VLPs (Warzecha, 2003).  What is 
particularly interesting about this research is that when the transgenic tuber, modified to 
express HPV L1 protein, in combination with a novel mucosal adjuvant (LT192G), was 
ingested by mice, it produced anti-HPV immunogenic responses.  This study also showed a 
humoral immunogenic boosting effect when HPV VLPs were delivered orally, indicating 
some specific immune response to the delivery of this vaccine to the mucosal immune 
surfaces.  This is important to our research, because if an immune response is observed after 
vaccination of the gastrointestinal tract, immune response through the pulmonary mucosa 
may also occur.  While VLPs are currently seen to be necessary for successful immunization, 
several studies under the direction of our collaborator Dr. Robert Garcea have shown that the 
individual HPV L1 subcapsid particles, or pentamer capsomeres, that show no evidence of 
self-assembly into VLPs, may have potent immunogenicity  (Moscicki 2005).  The HPV L1 
protein that we have researched is an approximately 300kDa protein, roughly pentagonal in 
shape with an inner void, appearing much like a “donut”  (Syrjanen 2005).  These proteins 
can be economically expressed in and purified from E. coli and may be very stable 
alternatives to VLPs.  The HPV L1 capsid proteins have also been shown to induce a strong 
cytotoxic T-Cell response and show tumor regression in mice (Swaminathan, Selvakumaran 
et al. 2009).  Individual L1 capsid proteins, synthesized from E. coli may lead to a second 
generation HPV vaccine as a stable, economical and effective, alternative to the VLP 
formulations. 
 
 
  
85 
 
5.2 Inhaled HPV Vaccine Theory 
  
While advancements have been made recently in HPV vaccination, there is still much 
room for improvement.  The cost of a current HPV vaccine series, $300-$500 in 2011, may 
be considered prohibitive in lower-income or poverty-stricken populations.  The extended 
vaccination series may become a problem particularly in areas without consistent healthcare, 
where women may not be able to access a health-care worker over the required 6 months.  A 
readily available and easily administered vaccination for HPV could greatly reduce the 
incidence and high mortality of cervical cancer, particularly in areas where women may not 
be able to get, or are culturally prohibited from getting, regular pap smears for early diagnosis 
of cervical cancer.  The difficulty of  injection (pain, contamination, compliance and disposal 
of sharps), required training of delivery staff and the 3-dose series, may lead to lower patient 
compliance and fewer women returning for the subsequent injections.  Even in the U.S., 
compliance with the recommended dosing schedule is spotty, with over 50% of doses 
delivered late in some areas (Ferlay J and 2010) and up to 45% of girls initiating the 
vaccination, yet not completing the series (Jemal, Bray et al. 2011).  Additionally, the 
requirement that the liquid vaccines be stored at 2-8 °C limits the geographical range that a 
mass vaccination campaign can cover.  These vaccines cannot be reliably delivered outside 
the cold chain and may be destroyed by freeze-thaw if the storage conditions are not 
constantly regulated.  This was the primary motivation to develop, test and optimize a dry-
powder, L1 capsid subunit-based HPV vaccine for delivery to the mucosal surfaces or for 
reconstitution and injection. 
 The goals of our formulation work on a dry powder HPV vaccine have been 
increased efficacy, ease of delivery and increased patient compliance.  This is currently 
measured in the conservation of protein and immunogenicity throughout processing of fine 
particle, properties, such as particle size, shape, density and moisture content and the stability 
  
86 
 
of the protein content, activity and particle properties during storage.  VLP-based HPV 
vaccine, formulated for liquid intranasal delivery, has shown an immune response in mice 
(Giuliano, Palefsky et al. 2011), and immune responses in mice have been observed after 
intranasal delivery of the L1 capsid proteins (CDC-ACIP 2011).  Nasal delivery carries with 
it several difficulties, including high loss to mucosal filtration, non-uniform delivery due to 
nasal differences/blockages and limited immune-active surfaces.   Therefore, our research the 
lungs were chosen as the primary targeted route of entry for mucosal delivery of the HPV L1 
antigen.   
The pulmonary system, a natural target of infectious microbes, contains mucosa-
associated lymphoid tissues (Crosbie and Kitchener 2007) and are patrolled by dendritic cells 
adapted for antigen presentation to T-cells (Widdice and Kahn 2006), conducive to 
generating good mucosal and humoral immune responses.  By delivering microparticles over 
the large surface the deep lungs, where particle removal is limited by phagocytosis or active 
transfer across the lung epithelium, the residence time of the vaccine powder can be increased 
.  Additionally, the lower concentration of native proteases in the alveolar fluid will reduced 
the chance of deactivation of the protein-based vaccine by enzymatic degradation which is a 
potential concern with oral and sublingual delivery.   
  As reported previously, pulmonary delivery through inhalation of a wet mist aerosol 
of live attenuated measles virus has been shown to have effectively immunized over 3 million 
children in Mexico for measles (Yuan, Estes et al. 2001).  Recent research has shown that 
pulmonary delivered dry powder influenza vaccines (influenza subunit proteins with no 
adjuvant) in mice induces a mucosal, systemic humoral, and cell-mediated immune response 
superior to conventional i.m. vaccination (Yuan, Estes et al. 2001).  While this study 
concentrated on mucosal immunity in the airways, the body’s lymphatic system has been 
shown to communicate immunity between distant lymphoid tissues in the body through the 
lymphatic system, leading to mucosal immunity in the genital mucosa as a result of 
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immunization in the respiratory tract (Chen, Casini et al. 2001).  In a 1998 study by Dr. 
Carole Balmelli et al, mice given a liquid formulation of HPV-16 VLPs administered nasally 
under anesthetic showed a significant HPV-16- specific IgG response in the blood.  What was 
particularly noteworthy was that high levels of HPV-16 specific IgG and IgA were also 
observed in the oral and vaginal mucosa (Ohlschlager, Osen et al. 2003).  This mucosal 
immunity was only noted when the mice were vaccinated under anesthetic, resulting in a 
significant deposition of the VLPs in the lungs.  Mucosal immunity to HPV would benefit the 
recipient by preventing initial infection and aiding in viral clearance.  Mucosal immunity 
would result in the production of HPV targeting IgA, a class of antibody specific to the 
mucosa which would inactivate the virus at the point of infection.   This additional protection 
may help to protect women with immunological disorders by producing a more robust 
immune response.  The mucosal (IgA) and humoral (IgG) antibodies present in vaginal 
mucosa have been noted to fluctuate throughout the estrous cycle, which may mean that the 
added protection of IgA in addition to IgG may provide more consistent protection. Mucosal 
immunity in the airways may also reduce the risk of HPV caused throat and neck cancer, 
increasing the direct value of this vaccine to males, in which HPV-related genital cancer is 
rare. Additionally, recent studies have shown the presence of HPV16 in certain types of lung 
cancer (Widdice, Bernstein et al. 2011), further justifying development of a pulmonary 
vaccine for HPV. 
5.3 Formulation  
 
 
HPV 16 L1 capsomere protein samples were initially obtained from Dr. Garcea’s lab 
in a buffer L solution consisting primarily of Tris Buffer, NaCl and glycerol.  Due to the 
favorable particle forming properties of myo-inositol with l-leucine demonstrated in the 
preparation of myo-inositol powders for previous toxicology tests, this mixture was chosen as 
the initial particle formulation.  The initial HPV powders were prepared and showed retained 
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protein content by SDS-PAGE analysis , but showed poor powder performance and appeared 
to aggregate excessively, as seen in Figure 5.1. Initial formulation studies concentrated on the 
removal of components of the Buffer L solution. 
 
 
Figure 5.1 SEM images of an aggregated L1 protein containing powder 
 Initially, glycerol was removed from the protein buffer.  Glycerol is a known 
plasticizer that is liquid at room temperature and is likely to cause particle cohesion and 
adhesion, by lowering the glass transition of the final powder.  One particularly large 
difficulty in designing a microparticle for delivery of a pharmaceutically active protein is 
consistency in the delivered dose.  The concentrations of the protein received varied between 
batches and, in order to maintain consistent dose the volume of buffer added to the stock 
solution for CAN-BD processing was varied.  At the concentrations used, between 1 and 10 
g/ml, the protein is not thought to have as much of an effect as the other excipients in the 
protein buffer, with concentrations up to 10 mg/ml in the initial stock.  Efforts were made to 
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produce consistent ratios of buffer to water in the stock solution for processing, and the 
optimal ratio was determined to be 1 part buffer to 3 parts aqueous solution, in order to 
maximize delivered dose with the minimum amount of buffer components. Of the buffer 
ingredients, Tris buffer was considered necessary for protein stability and NaCl was required 
to prevent protein precipitation.  Tris buffer has been noted to result in the collapse of 
lyophilized material (Niccolai, Mehta et al. 2011).  It is believed that during the drying phase 
high concentrations of salt may reduce the vapor pressure of the liquid droplet, leading to wet 
particles resistant to drying and likely to stick to one another or the filter upon collection .  
Several different salt concentrations were processed and reducing salt concentration showed 
some improvement of powder properties.   
 Other studies were conducted to maximize protein content of the stock solution by 
dialyzing the protein into a solution containing myo-inositol, l-leucine and the buffer 
components at roughly 10% TDS.  This proved successful in making better-performing 
powders, in terms of dispersibility and respirable fraction.  Large quantities of the 
buffer/excipient solution were require relative to the resulting stock solution and powder 
property improvement was not thought to be sufficient to justify the additional dialysis step.   
 
5.3.1 Inclusion of ammonium acetate 
 
Previous studies with spray dried gold nanoparticles, produced by Dr. Feldheim’s 
group, in solution with 8 mM ammonium acetate had shown significant respirable fraction 
improvement of the myo-inositol/ l-leucine powder formed by CAN-BD processing.  Particles 
produced with this formulation appear hollow and show some evidence of burst hollow 
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particles in SEM images, Figure 5.2.
 
Figure 5.2 Hollow particle of myo-inositol/leucine and gold nanoparticles made with 8 
mM ammonium acetate stock solutions. 
  The concentration of gold nanoparticles was assumed to be too small to have an 
appreciable effect on the particle properties, leading to experiments where ammonium acetate 
was added to myo-inositol/l-leucine stock solutions and processed by CAN-BD.   A general 
increase in respirable fraction was noted in powders formulated with between 0.4% and 1.5% 
ammonium acetate, with maximum increases of up to 10% in particles below 5.8 m in 
aerodynamic diameter and an increase of up to 15% in particles below 3.3 m in 
aerodynamic diameter, Table 5.1. 
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Formulation Average ± Average ± 
 
%<3.3 
µm 
%<3.3 
µm %<5.8 µm 
%<5.8 
µm 
myo-inositol/leucine (98.5:1.5) 18.3 1.9 56.7 3.5 
+ 
    0.4% NH4C2H3O2 28.9 2.0 63.8 3.0 
0.8% NH4C2H3O2 20.6 1.6 50.3 4.0 
1.5% NH4C2H3O2 21.9 1.3 56.1 2.9 
     0.4% NaC2H3O2 26.8 1.0 59.2 3.1 
0.8% NaC2H3O2 23.1 1.9 55.1 2.7 
1.5% NaC2H3O2 26.6 0.3 70.3 0.6 
Table 5.1 Particle size by ACI for different additions of acetate salts in a myo-
inositol/leucine based powder 
 
In order to determine the source of the improvement powders were prepared with the 
addition of sodium acetate and showed similar improvements of respirable fraction.  Powders 
formulated with ammonium chloride at the same molar concentrations used in the ammonium 
acetate studies, did not show improvement;  in fact the respirable fraction dropped 
significantly compared to powder using only myo-inositol and l-leucine. This implies that the 
presence of acetate may be the primary factor in the respirable fraction improvement, but the 
ammonium ion may be working in concert with the acetate ion.  We can propose several 
explanations for the improvement in the respirable fractions of these powders.  The addition 
of ammonium acetate or sodium acetate may have beneficial pH buffering effects, the 
ammonium ions may be forming ammonium bicarbonate during processing or the acetate 
may be interacting beneficially with myo-inositol or l-leucine beneficial to fine particle 
formation.   
 A solution of ammonium acetate acts as a buffer with a pH of 7.  While extensive 
studies have not been conducted, it is thought that pH may play a role in the quality of 
powder produced by CAN-BD processing.  pH effects may come into play during the 
emulsification of the aqueous solution with at the mixing tee.  The concentration of dissolved 
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carbon dioxide may be closely related to the pH of the solution through the carbon dioxide 
carbonic acid equilibrium. 
                    
       
            
This may be altered by the presence of the acetate or ammonium ion, resulting in differences 
in the solubility or dissolution of carbon dioxide in the process liquids or the droplets of the 
spray.  Additionally, the pH of the spray solution may influence the solubility of the dissolved 
solids in the spray droplets.  If the dissolved solids are less soluble, a solid skin will form 
around the drying droplet at an earlier stage (Balmelli, Roden et al. 1998), resulting in a 
hollow particle of low density and high dispersibility.  This is unlikely as pH measurements 
of the formulation after the addition of each individual component showed that the Tris buffer 
in the protein solution dominates the pH of the liquid formulation.  myo-Inositol/leucine 
placebo formulations prepared with no additives or 11 mM ammonium acetate, sodium 
acetate or ammonium nitrate showed different pH values with the addition of the additives, 
but all solutions exhibited a consistent pH of 8.2 after the addition of the tris buffer solution 
(buffer L). 
 Another proposed explanation is that during the drying process, solid ammonium 
bicarbonate may be produced in the drying droplet solution.  Ammonium bicarbonate has 
been added to other spray-dried formulations to improve powder properties (Ohlschlager, 
Osen et al. 2003).  The proposed method of powder improvement is that ammonium 
bicarbonate will spontaneously decompose to ammonia and carbon dioxide gas and water at 
temperatures between 30 and 60 °C. 
       
 
⇒                      
This would produce additional gas inside the drying droplet (beyond the dissolved CO2) 
during the drying process.  If the solution is sufficiently viscous, the dried particle could 
maintain a hollow or porous nature.  The process of CAN-BD is thought to operate in part, 
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based on the solubility of carbon dioxide in the aqueous solution of the compound or salts of 
interest.  Additional droplet dispersion and a decrease in initial droplet size are thought to 
lead to smaller dry particles after drying and collection.  The addition of ammonium to the 
stock solution may result in a “reservoir” for dissolved carbon dioxide, as ammonium 
bicarbonate.  This could lead to gas release during the drying phase of the powder formation, 
rather than immediately at the decompression at the end of the spray restrictor.  If the gas 
were to be released when the drying liquid droplet has a higher viscosity, the porous character 
could be more conserved in the final dried particle, much like the production of a froth in a 
viscous solution vs. a dilute solution.  It can be seen, in SEM images, that the particles 
produced by the addition of ammonium acetate are partially hollow or porous (Figure 5.2).  
The combination of ammonium and acetate may lead to production of more stable 
ammonium bicarbonate, resulting in the production of gasses beneficial to the final quality of 
the powder.   
 Ammonium acetate is commonly used to precipitate particles (Ohlschlager, Osen et 
al. 2003) and proteins    If this is occurring during the atomizing phase of the CAN-BD 
process it may result in changes in the solubility of myo-inositol beneficial to the production 
of high quality powder.  The manner in which these changes would be beneficial is not 
immediately apparent, and likely complex in nature, but, the reduction of solubility of myo-
inositol due to myo-inositol acetate adduct/ l-leucine interactions could result in the formation 
of a dry (or viscous liquid) “skin” earlier in the drying process of the drying liquid droplet.  
This would result in the formation of a larger hollow particle of lower density.  Lower density 
particles would be easier to disperse and may display lower particle aggregation tendencies 
(Holmgren and Czerkinsky 2005).  Lower density particles will have a lower surface area to 
mass ratio, leading to weaker particle bonding and the larger diameter could make the 
particles more likely to interact with a turbulent dispersal air flow. 
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5.3.2 Final Formulation 
 
The formulation of the HPV protein powder in aqueous solution used in our more 
advanced experiments contained ammonium acetate at roughly 11 mM,  with a total 
dissolved solids content of 110 mg/ml consisting of the components displayed below and 
resulting in a powder with the properties listed in the Table 5.2. 
material concentration in liquid concentration in dry powder 
  mg/ml % (mass/mass) 
myo-inositol 100.3 91.6 
l-leucine 1.6 1.4 
ammonium acetate 0.9 0.8 
NaCl 2.8 2.5 
Tween 2.4 2.2 
Tris Buffer 1.4 1.3 
DTT 0.1 0.1 
EDTA 0.1 0.1 
Table 5.2 Components of L1 protein based HPV vaccine powder 
 
Protein concentrations varied between 1 to 5 g/mg dry powder, depending on the 
concentration in the provided protein sample.  It should be noted that in lyophilized 
formulations, both Tris buffer and sodium acetate are known to cause collapse of the 
lyophilized cake near their glass transition states of -81°C and 80 °C, respectively 
(Lambrecht, Prins et al. 2001).  This may have resulted in the production of poor performing 
particles; however, this difficulty was overcome by the addition of excipients with high glass 
transition temperatures in the formulation.  
 Powders were processed using standard CAN-BD processing conditions with an 
average drying gas temperature of 70 °C, to avoid the formation of the alternate polymorph of 
myo-inositol at lower temperatures.  Powder was collected in glass vials from the Nylon filter 
by scrapping ,with metal spatulas, in a low humidity (<15% RH) environment.  The vials 
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were sealed with molecular sieve desiccant packets in aluminum foil-polymer laminate film 
overwrap.   
 Placebo powder used in testing was prepared using this formulation with bovine 
serum albumin (BSA) at about 1.7 g/mg dry powder.  BSA is a common protein model that 
has been shown to be well-tolerated when delivered by inhalation to rats (Folkesson et al 
1992).  Placebo powder without this added protein was not analogous to the active powder 
and was observed to have different physical properties (Figure 5.4) than the active HPV 
protein powder (Figure 5.3).  This implies additional beneficial effects due to the addition of 
a low concentration of protein, possibly due to enhanced “skin” formation of the drying 
particle, leading to hollow particles.        
 
Figure 5.3 CAN-BD processed HPV L1 protein powder 
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Figure 5.4 CAN-BD processed placebo powder with no protein 
It can be seen in Figure 5.3 that the protein powder did have some hollow properties, 
as shown by holes in some particles and the “collapsed” appearance of some of the larger 
particles.  The powder without the addition of protein exhibited unique morphology with 
some angled particles that may imply some crystalline content.   
 The HPV L1 protein containing powder was tested for protein content by SDS-PAGE 
and for immunogenicity by ELISA using HPV16 L1 specific antibodies by the Garcea 
research group, Figure 5.5.   
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Figure 5.5 SDS PAGE gel ( prepared by Dr. Elizabeth Gersh of the Garcea lab) of 
reconstituted CAN-BD processed L1 protein powder vs L1 stock   
 
Figure 5.6 Results of ELISA testing of reconstituted CAN-BD processed L1 protein 
powder (P) and 10% myo-inositol/l-leucine solution with added stock L1 protein at the 
same concentration.   
In Figure 5.5 it can be seen that the bands for the CAN-BD processed L1 protein 
powder are identical to the bands observed for the stock protein in a 10% myo-inositol/l-
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leucine solution.  The protein concentration of the positive control (M/L) was determined 
based on the theoretical concentration of the reconstituted protein powder, based on the initial 
amount of added L1 protein.  The nearly identical intensities of the bands demonstrated 
excellent conservation of protein content through processing.  ELISA testing (Figure 5.6) 
tested positive for  the L1 and V5 epitopes of the HPV16 L1 protein.  This shows the 
presence of the L1 protein with the correct folding (V5) for antigenic response. 
HPV16 L1 capsomere specific ELISA testing was conducted on a sample powder and 
showed good  conservation of immunogenicity  through processing, providing promising 
evidence that we had formulated an active dry powder formulation of HPV16 L1 protein 
antigen.  Ongoing studies in Sprague-Dawley rats will determine the immunogenicity of this 
powder delivered by pulmonary insufflation and reconstitution with i.m. injection. 
5.4 in vivo Immunogenicity Test Design 
 Sprague Dawley rats, while not naturally susceptible to Human Papillomavirus 
serotype 16, were chosen as an appropriate animal model because of the extent of 
characterization and common use as an animal test model.  Initial studies suggested that 
larger, 11-12 week old animals would be required for dosing by insufflation, with females 
weighing more than 250 g and males weighing more than 350 g .  A total of 32  animals (16 
male/16 female and divided evenly among the groups) were included in the test, divided into 
the groups listed in Table 5.3. 
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Group Number mg Powder Dose  g L1  Protein Dose  
Insufflation Pilot Low Dose 2 1 mg placebo  n/a 
Insufflation Pilot High Dose 2 2 mg placebo  n/a 
Insufflation Low Dose 4 1 2.4 
Insufflation High Dose 4 2 4.8 
Sublingual Low Dose 4 1 2.4 
Sublingual High dose 4 2 4.8 
Injection Low Dose 4 1 2.4 
Injection High Dose 4 2 4.8 
Injection Control 4 
 
Dilute Gardasil  
Total 32 
  
Table 5.3 Powder testing group assignments 
 
All animal studies were conducted at High Q Research, Ft. Collins CO (HQR) and all 
animal handling was conducted by HQR facility staff.  The animal testing procedure was 
approved by the facility’s IACUC panel.  Tail bleed samples were collected before dosage 
and at designated time points after initial dosing up to a final bleeding and sacrifice at study 
day 60.  At least 5 minutes before dosage, animals were anesthetized by injection with 
ketamine/xylazine, dosed according to animal weight by the facility veterinarian.  The 
immunogenicity experiment was designed such that animals received an initial dosing on 
study day 0 and a second dosing on study day 20.  An immunogenic response is indicated by 
the presence of HPV16 specific antibodies in blood samples after dosage and an increased 
production of HPV16 specific antibodies after the second delivery.  
 A Model DP-4 Dry Powder Insufflator (PennCentury) was initially loaded with 
about 6 mg of the powder of interest and dispersed into a contained vessel.  This acted to 
prime the device, providing an initial powder coating of the loading chamber, which, from 
experience, improved the powder delivery.   Immediately before delivery, the empty device 
was weighed and loaded with 6 mg of the powder of interest.  Anesthetized animals were 
immobilized on an angled board, a drop of lidocaine was placed on the vocal cords to prevent 
tracheospasm. HQR staff then placed the loaded insufflation device into the trachea with the 
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device tube opening about 1-3 mm from the initial airway branching.  HQR staff quickly 
dispensed 1 mL of air from a 3 mL syringe after which, the device was removed, weighed, 
and cleaned. The mass of powder delivered was determined by the difference between the 
loaded weight of the device and the weight of the device after delivery.  
5.4.1 Placebo Insufflation Pilot Group 
 
An initial pilot study was conducted to prepare a more informed insufflation 
technique and determine tolerance of the animals for insufflated powder.  This will also serve 
as a de facto negative control group.   Powder Placebo containing BSA was dispersed directly 
into the lung of the animals using the previously stated insufflation method.  Desired dosage 
was 1 mg powder for the low dose group and 2 mg powder in the high dose group as the 
range of previously insufflated powder dosage with rats has been reported to be between 1 
mg and 5 mg (Valdespino-Gomez, Garcia-Garcia et al. 2006).  Variabilities in the powder 
and delivery device led to a larger range of powder delivery in the pilot group.  Animals 
received  0.5 mg to 4.1 mg of placebo powder insufflated into lungs, with no immediate or 
subsequently observed adverse effects.  Animals were dosed on pilot study Day 0 and again 
on pilot study Day 20, and were sacrificed on pilot study Day 60.  The pilot test showed that, 
while it was difficult to deliver a consistent dose, Sprague-Dawley rats could tolerate doses 
up to 4.1 mg of insufflated placebo powder with no detectable adverse effects. 
5.4.2 HPV16 L1 Protein Powder Insufflation Group 
 Insufflation of the active powder was conducted in the same manner as the placebo 
group.  The active HPV L1 protein powder used was DM110724, formulated with myo-
inositol, l-leucine and trace ammonium acetate with a HPV16 L1 capsomere protein dose of 
2.4 g/mg . This powder had been tested by ELISA in the Garcea lab and showed appropriate 
immunogenicity.  Test animals received the powder with no observed adverse effects.  
Powder was delivered to the High Dose (at least 2 mg) and Low Dose (at least 1 mg) groups 
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using the insufflation method previously reported.  Unfortunately, due to method variability, 
the powder delivered by insufflation was not exactly within these ranges, powder delivered 
and protein doses are shown in Table 5.4.  The powder was insufflated directly into the 
trachea with no observed adverse effects. 
 
Day 0 Day 0 Day 20 Day 20 
Group Powder Dose mg Protein Dose µg Powder Dose mg Protein Dose µg 
Low 1.1 2.6 3.3 7.9 
Low 0.7 1.7 2.8 6.7 
Low 3.8 9.1 2.2 5.3 
Low 1.4 3.4 2.7 6.5 
High 1.6 3.8 2.2 5.3 
High 3.3 7.9 2.7 6.5 
High 4.4 10.6 3.0 7.2 
High 2.0 4.8 2.0 4.8 
Table 5.4 Dosage of HPV16 L1 protein powder insufflation group. 
  
5.4.3 HPV16 L1 Protein Sublingual Pellet 
Pellets, or wafers, for sublingual delivery were formulated with 1 mg (Low Dose) or 
2 mg (High Dose) of DM110724, formulated with myo-inositol, l-leucine and trace 
ammonium acetate with a HPV16 L1 capsomere protein dose of 2.4 g/mg, bulked with 
placebo powder and a cellulose-based excipient to a total mass of about 10 mg.  Pellets were 
formed by compression in a pellet press at a deliberately increased relative humidity (40% 
RH) to make compacted pellets with sufficient cohesion.  During testing, pellets were placed 
under the tongues of anesthetized rats.  One drop of water was added to the powder at 1 
minute and 2 drops were added at 2 minutes with addition drops of water added at 15 minutes 
after delivery.  The pellets were observed to form a thick slurry under the tongue and were 
left in the animal’s mouth when they were returned to their cages.  No direct adverse 
reactions were noted. 
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5.4.4 HPV16 L1 Protein Powder Reconstitution and Injection 
 Powder was reconstituted in a dilute mixture of Alhydrogel 85 and sterile saline.  The 
diluent was designed to contain the amount of alum adjuvant comparable to the diluted 
Gardasil in the control group (22.5 g/mL).  The diluent was prepared by diluting 0.25 mL 
Alhydrogel 85 to 10 mL using sterile saline and then diluting 1 mL of this stock to 10 mL 
with sterile saline.  Stock diluents were shaken well before mixing and the final diluent was 
well agitated before adding them to the powder.  Powder for reconstitution, DM110724, 
formulated with myo-inositol, l-leucine and trace ammonium acetate with a HPV16 L1 
capsomere protein dose of 2.4 g/mg, was packaged into sterile Eppendorf tubes with 10 mg 
for the Low Dose and 20 mg for the High Dose.  After diluent was added, the container was 
lightly agitated until the powder was completely dissolved.  The reconstituted powder was 
allowed to sit at room temperature for at least 1.5 hours before injection.  Both doses 
appeared to be slightly cloudy and contain distinct cloudy aggregates which settled when not 
thoroughly agitated.  The reconstituted suspensions were shaken well and transferred to the 
veterinarian who injected 0.1 mL into the thigh of the anesthetized animals.  The dose was 
designed such that the animals would receive 2.4 mg of the HPV16 L1 capsomere protein in 
the Low Dose group and 4.8 mg of the HPV16 L1 capsomere protein in the High Dose group. 
One test animal in the Low Dose injection group was found dead after the testing on Day 0; 
this was attributed by the veterinarian to a reaction to the anesthesia. No other animals 
showed immediate, or detectable long-term, adverse reactions to injection. 
5.4.4 Gardasil Positive Control Group 
A control group received an i.m. injection of a 1:20 dilution of Gardasil with sterile 
saline.  The dilution was prepared by agitating the Gardasil vial and diluting 0.25 mL of the 
Gardasil with 0.75 mL of sterile saline.  The diluted suspension was used within 30 minutes 
of dilution.  The tube was shaken well and transferred to the veterinarian who injected 0.1 mL 
into the left thigh of the animal.  There was only one dose group for the Control testing.  The 
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dosing was designed to deliver 2 g of the HPV16 VLP protein, comparable to the low Dose 
of our reconstituted powder.  No adverse effects were noted in any of the animals in the 
control group.  The Gardasil positive control group should give an immune response 
reference, using an FDA approved HPV 16 vaccine with proven efficacy, for comparison 
with the powder test groups. 
5.4.5 Study Preliminary Results 
 No results of blood assays are available at the time of the writing of this dissertation, 
but they should be forthcoming in several weeks after final sacrifice on day 60.  The powder, 
containing myo-inositol, l-leucine, ammonium acetate, HPV16 L1 capsomere protein and 
buffer components was well tolerated by insufflation (up to 4.4 mg), sublingual delivery and 
delivery after reconstitution with alum adjuvant.  No immediate adverse effects or reactions 
were observed and the results of the immunogenic blood tests are eagerly anticipated and will 
be published when thoroughly analyzed.   
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________________ 
Conclusions 
________________ 
 Vaccines have served to greatly increase the longevity and quality of human life, but 
delivery by injection carries inherent dangers and costs.  Vaccination through the pulmonary 
inhalation route has been shown to provide good immune protection and warrants further 
research.  Our research has developed an effective and stable dry powder measles vaccine for 
inhalation produced by the CAN-BD process. We have developed various methods of 
characterization for this powder to optimize running parameters and observe stability.   
 Powder X-ray diffraction and Differential Scanning Calorimetry analysis show that 
the final vaccine formulation was an amorphous glass.  NMR comparison of different batches 
have revealed differences and aided in optimizing preparation procedures.  A method of 
determining the viral activity in particles of different sizes was developed and used to show 
that the powder activity was homogenous in the particle size ranges important for lung 
deposition. 
 Pure myo-inositol powder was produced by the CAN-BD process and found to be 
crystalline.  Analysis of this crystal powder shows the existence of two anhydrous crystalline 
forms, one representative of the expected crystalline structure and one with no previously 
reported pXRD diffraction pattern, produced by different process parameters.  The novel 
polymorph was shown to be metastable and recrystallize into the native form when heated to 
145 ºC or stored at room temperature for extended periods of time.  A powder containing 
myo-inositol and l-leucine was prepared for toxicity testing and shown to be well-tolerated 
when delivered to rats by at-liberty breathing. 
 With the goal of reducing the global mortality and morbidity due to Human 
Papillomavirus infection, and the resulting cervical, penile, head and neck and other cancers, 
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a dry powder HPV protein subunit vaccine was developed. Protein material was provided by 
Dr. Robert Garcea;s lab.  The myo-inositol based formulation was designed and improved 
with the addition of ammonium acetate in low concentrations.  The powder was shown to 
retain protein content and the proper epitope for antigenic activity by SDS-PAGE and ELISA 
testing.  This powder was used in immunogenicity tests with Sprague Dawley rats and shown 
to be well tolerated when delivered by insufflation, sublingual wafer and injection after 
reconstitution with alum adjuvant.  The results of this immunogenicity test are forthcoming at 
the time of the writing of this dissertation and will be published once they have been 
collected and analyzed. 
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